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Abstract 
Pertussis, caused by Bordetella pertussis, is a vaccine-preventable disease affecting persons 
of all ages. Despite vaccination with either the whole-cell or acellular vaccine, the burden of 
pertussis has increased worldwide. The acellular vaccine was licensed in South Africa in 
2009, replacing the whole-cell vaccine; however, due to no active surveillance, pertussis is 
underestimated in this country. This study describes the burden of disease caused by 
B. pertussis and other Bordetella species in patients with severe respiratory illness (SRI), 
influenza-like illness (ILI) and controls.  
 
Prospective, active surveillance was conducted amongst SRI and ILI patients and controls at 
two sentinel sites in South Africa. Patients who met the case definitions were enrolled from 
May 2012 to October 2014. Clinical and demographic data were collected. Induced sputum 
was collected from SRI patients only and combined nasopharyngeal/oropharyngeal 
specimens were collected from all patients and controls. Real-time polymerase chain reaction 
(PCR) was used to target the insertion sequences IS481, pIS1001, hIS1001 and pertussis toxin 
gene ptxS1. All data were analysed in Microsoft Excel (Microsoft Corporation). Statistical 
significance was determined using the chi-squared test and univariate logistic regression at p 
<0.05 for all parameters. 
 
Of 8569 cases that were enrolled and tested, 118 [1.4%, 118/8569 (95% CI 1.1 – 1.6)] were 
positive for B. pertussis of which 2% [80/3982 (95% CI 1.6 – 2.5)] presented with SRI, 1% 
[32/3243 (95% CI 0.7 – 1.4)] with ILI and 0.4% [6/1344 (95% CI 0.2 – 1.0)] were 
asymptomatic. Positive cases were stratified into confirmed pertussis and probable pertussis 
based on cycle threshold (Ct) value cut-offs generated by real-time PCR for IS481. Within 
the SRI population, there were more probable than confirmed pertussis cases [51/3982, 1.3% 
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vs. 29/3982, 0.7%; p=0.02] and within the ILI group there were 0.5% confirmed and probable 
cases, respectively [15/3243, 0.5% vs. 17/3243, 0.5%; p=0.86]. The highest detection rate of 
pertussis in SRI positive cases was in the ≥65 year olds (2.8%, 6/208) and for the ILI positive 
cases the highest detection rate was in the 1-4 year olds (1.5%, 9/614). Pertussis disease was 
observed mainly in the winter and spring months with a 15% increase in disease detected in 
August 2014. The B. pertussis attributable fraction was 67% (95% confidence interval [CI] 
18.49 – 86.63) for SRI positive cases. Fifty-eight percent (46/80) of B. pertussis positive 
cases were co-infected with respiratory bacteria (Streptococcus pneumoniae, Haemophilus 
influenzae, Legionella spp. or Mycoplasma pneumoniae) or viruses (influenza, respiratory 
syncytial virus (RSV), human metapneumovirus or other viruses (adenovirus, enterovirus, 
parainfluenza or rhinovirus). HIV status and full pertussis vaccination for age did not affect 
B. pertussis positivity.  
 
B. parapertussis was detected in 1% [40/3982 (95% CI 0.7 – 1.4)] of the SRI population, 
0.6% [18/3243 (95% CI 0.3 – 0.9)] of the ILI population and in 0.1% [2/1344 (0.02 – 0.5)] of 
asymptomatic individuals. The highest detection rate for the SRI (1.6%, 8/497) and ILI 
(1.5%, 9/614) positive cases were in the 1-4 year olds. The B. parapertussis attributable 
fraction was 80% (95% confidence interval [CI] 12.52 – 95.38) for SRI cases. Four cases 
tested positive for B. bronchiseptica, of which one individual was HIV positive.  
 
B. pertussis, B. parapertussis and B. bronchiseptica were detected despite the case definitions 
not being ideal for the detection of these pathogens. Bordetella spp. was detected in all age 
groups tested. This study generates baseline data for pertussis in South Africa and 
surveillance is ongoing. 
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1. Literature review 
1.1. Background 
Pneumonia is a severe lower respiratory tract infection that is characterised by pus and fluid 
build-up in the alveoli of the lungs, making breathing difficult (1). It is most prevalent in sub-
Saharan Africa and South Asia (2;3). Pneumonia is differentiated into community-acquired or 
hospital-acquired infection and is associated with morbidity and mortality in patients of all 
ages, but is more common in children <5 years of age and the elderly (4). In 2011 
approximately 120 million cases of childhood pneumonia were estimated globally (5). The 
human immunodeficiency virus (HIV) pandemic has resulted in an increased incidence of 
pneumonia globally (6), and in sub-Saharan Africa where HIV is epidemic, pneumonia is 
responsible for severe illness, hospitalisation and mortality in HIV-infected children (7). In 
HIV-endemic areas, pneumonia is the leading cause of hospitalisation; however most cases 
are only diagnosed HIV positive upon admission (8). Treatment of pneumonia is challenging 
due to the many respiratory pathogens that may cause this infection, the difficulty in making 
a clinical and aetiological diagnosis, and the lack of a single antimicrobial drug that is 
effective against all the pathogens associated with pneumonia (9).  
 
Pneumonia is caused by many respiratory pathogens, both viral and bacterial (10), however, 
it is most commonly associated with bacterial pathogens (1). There are many diagnostic 
methods employed to identify these pathogens such as bacterial culture and microscopy, 
however these techniques only result in approximately 20% to 25% identification of total 
CAP cases due to limited sensitivity (11). Other methods such as identification of bacterial 
antigens, e.g. pneumococcal antigen with BinaxNOW
®
 (12), and serology, are either unable 
to distinguish carriage from disease or provide information retrospectively and are therefore 
not useful for treatment (11). Of the many techniques available, polymerase chain reaction 
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(PCR) is a popular method for identification due to its increased sensitivity, being able to 
detect the minimum number of bacterial cells (13) and has the ability to detect the causative 
agent after a patient has been on antibiotic treatment (14). The technique is also specific in its 
ability to detect only the pathogen of interest. Since PCR is rapid, a diagnosis can be made 
earlier than culture resulting in more timely commencement of treatment (13).  
 
Studies have shown that the most common bacterial pathogens that cause pneumonia are 
Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus (1;10), 
Moraxella catarrhalis, group A streptococci, Mycoplasma pneumoniae, 
Chlamydia pneumoniae (1) and Bordetella pertussis (15). There have been studies 
highlighting the bacterial aetiology of pneumonia and describing the burden of disease caused 
by each of the pathogens; however few studies have focussed on B. pertussis as an 
aetiological agent. 
 
1.2. B. pertussis 
Pertussis, caused by B. pertussis, is a vaccine-preventable respiratory disease affecting 
persons of all ages (16). The organism belongs to the genus Bordetellae and is one of eight 
other Bordetella species namely: B. parapertussis, B. bronchiseptica, B. holmesii, B. avium, 
B. trematum, B. hinzii, B. petrii and B. ansorpii. B. pertussis, B. parapertussis, 
B. bronchiseptica and B. holmesii are known to cause disease in humans; however, 
B. pertussis and B. parapertussis are the common causative agents of disease.  
 
B. pertussis caused its first well documented outbreak of pertussis in 1578, and in 1679 the 
disease was named whooping cough (17). The bacterium was discovered in 1900 by Jules 
Bordet and Octave Gengou after examining sputum from a 6-month-old baby suffering from 
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whooping cough. B. pertussis is a Gram-negative coccobacillus that is catalase positive and 
oxidises amino acids (17;18). B. pertussis is aerobic and requires an optimum temperature 
between 35-37°C for growth on specialised media without fatty acids, metal ions, sulphides 
and peroxides. Culture media such as Bordet-Gengou and Regan-Lowe charcoal medium are 
used for B. pertussis isolation with colonies appearing as mercury-like droplets. 
 
 
Figure 1: Electron micrograph showing outer structure of B. pertussis ATCC 9797. 
 
1.2.1. Pathogenesis and clinical manifestation  
B. pertussis is a strict human pathogen, therefore modelling the disease in animals and 
understanding its pathogenesis is difficult (19). Transmission is from person-to-person via 
respiratory droplets from an infected person and disease is toxin mediated (20). The disease 
cycle includes the following process (16;17;19): B. pertussis produces filamentous 
hemagglutinin, pertactin, and 2 fimbrial proteins which aid in attachment of the bacterium to 
the cilia of the respiratory epithelial cells of the nasopharynx. The organism then replicates 
and spreads to the ciliated epithelial cells of the trachea and bronchi in the absence of an 
immune response. B. pertussis then produces pertussis toxin, tracheal cytotoxin and adenylate 
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cyclase toxin which damage the respiratory epithelial cells and alveolar macrophages. This 
damage results in hyperlymphocytosis and impairment of chemotaxis resulting in the host 
immune defences being evaded.  
 
The most common systemic manifestation of pertussis are leucocytosis and lymphocytosis 
(21). Sensitisation to histamine, serotonin and the beta-islet cells of the pancreas has also 
been observed. The disease manifests in 3 stages (17;18;22;23). The initial catarrhal phase is 
characterised by symptoms of the common cold which include rhinorrhoea, fever and 
occasional cough. In this stage the patient is most infectious. The catarrhal stage is followed 
by the paroxysmal phase where patients have the typical symptoms of pertussis which 
include whooping cough, paroxysms and posttussive vomiting. This phase is followed by the 
convalescent phase were disease symptoms are less severe. Disease symptoms in children 
with pertussis are severe, while adults and adolescents may have asymptomatic/atypical 
infection (16;24). 
 
1.2.2. Laboratory diagnosis  
The ideal specimen type for the diagnosis of pertussis is either a nasopharyngeal aspirate or a 
posterior nasopharyngeal swab (17). These specimens are ideal as they contain the ciliated 
epithelial cells to which B. pertussis attaches. 
 
Together with clinical history, culture, direct fluorescent antibody (DFA), serology and PCR 
are used for the diagnosis of pertussis (24). Culture of nasopharyngeal specimens, the gold 
standard, is highly specific and the most common method of choice. This method is 
recommended during the catarrhal stage of illness. However, since B. pertussis requires 
between 3 to 10 days of incubation, culture becomes difficult, especially when a rapid 
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diagnosis is required or if a patient has been previously treated with antibiotics (17). Serology 
is usually used for the diagnosis of pertussis in older vaccinated children, adolescents and 
adults and is recommended as a diagnostic tool when the disease has progressed with 
minimal clinical signs and symptoms (25). A limitation of this method is that the serological 
tests measure antibodies that could result either from infection or vaccination, making 
diagnosis inaccurate. DFA can offer rapid diagnosis; however, this technique requires 
specialised trained staff and has a high false-positive rate (17;23). DFA can be used to screen 
for pertussis and it is recommended that a DFA result be confirmed by culture or PCR. Due 
to these limitations, real-time PCR is increasingly used for diagnosis (25-28). Real-time PCR 
is an ideal diagnostic method during the first three weeks of cough. However, real-time PCR 
identification of B. pertussis is hampered by the lack of availability of validated and ideal 
gene targets. 
 
The most common gene target for pertussis diagnostics is the IS481 insertion sequence 
present in multiple copies (50-238) in the B. pertussis genome; however there are problems 
associated with this target. The IS481 gene is not species specific and can be detected in 
B. bronchiseptica and B. holmesii, making diagnosis difficult (20;29). A qualitative 
assessment of pertussis diagnostics in the United States revealed that 5% of laboratories 
reported false positive results in proficiency testing using IS481 only (30). Another 
proficiency testing study in Europe found that all laboratories that use only IS481 for 
diagnosis reported specimens positive for B. bronchiseptica and B. holmesii as B. pertussis 
(31). Pseudo-outbreaks linked to patient clinic surfaces contaminated by IS481, resulting in 
contamination of specimens, were reported in the United States (32;33). This phenomenon 
occurred as a result of using IS481 only as well as not having cycle threshold (Ct) value cut-
offs for the real-time PCR. Outbreaks of respiratory illness in New Hampshire, 
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Massachusetts, and Tennessee between 2004 and 2006 were falsely attributed to B. pertussis 
due to the use of IS481 only (34). These issues can be overcome by incorporating the 
pertussis toxin subunit gene (ptxS1) into the real-time PCR assays (26-28). This gene is 
present as a single copy in the B. pertussis, B. bronchiseptica and B. parapertussis genome 
and it can help in differentiating Bordetella spp. (20). In addition, it is important to have 
sufficient and stringent control measures in place so that contamination can be minimised and 
easily detected. 
 
1.2.3. Epidemiology 
The whole-cell pertussis vaccine was introduced in the 1940’s and was implemented in 
industrialised countries (16-18). It was later found to be reactogenic and associated with 
adverse side effects including chronic neurologic damage, sudden infant death syndrome, 
infantile spasms and hypsarrhythmia (18;35). Due to the side effects the acellular pertussis 
vaccine was developed and introduced in the 1980’s (16). The acellular vaccine is composed 
of up to 5 purified B. pertussis antigens (2 fimbrial antigens, pertactin, filamentous 
haemagglutinin, and pertussis toxin) in various combinations and concentrations (17). 
 
Despite many countries having high vaccine coverage with either whole-cell or acellular 
vaccines, the incidence of pertussis has increased during the last 20 years (28;36-41). The 
marked increase has been attributed to many factors including increased awareness by 
clinicians, use of more sensitive molecular techniques for diagnosis (28;38), the use of 
serological markers for identification of infection in adolescents and adults who usually are 
the asymptomatic carriers of pertussis infection (37), and waning vaccine immunity (40;42). 
Marked pertussis increases have been noted in the United States (36), Canada (38), Denmark 
(37) and Tunisia (28) amongst other countries. In addition, recent studies have shown that the 
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increase could be attributed to the evolution of the B. pertussis genome with mutations 
observed in the virulence-associated genes coding for the pertussis toxin A subunit, pertactin, 
serotype 2 fimbriae, serotype 3 fimbriae and the promoter for the pertussis toxin (43;44). 
Studies in the United States have shown that some B. pertussis strains do not express the 
vaccine antigen pertactin (45;46). Pertactin-deficient B. pertussis was also observed in France 
and these isolates were shown to be as virulent as the pertactin-expressing isolates (47). 
B. pertussis isolates analysed from 1998 to 2009 in Europe showed an increased prevalence 
of isolates that contain the novel pertussis toxin promoter ptxP3 allele replacing the ptxP1 
allele (48). 
 
The whole-cell vaccine was introduced in South Africa in January 1950 and was later 
replaced by the diphtheria tetanus acellular pertussis (DTaP) vaccine in April 2009. There are 
limited data on the prevalence of pertussis in South Africa. Only studies from the Western 
Cape (41;49;50) and Free State province (51) have been published thus far. These studies had 
a small sample population and results were not representative of the South African population 
more broadly. Therefore, there is a need for more systematic pertussis surveillance in South 
Africa to better understand B. pertussis, also considering the high HIV burden. 
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1.3. Pneumonia surveillance in South Africa  
This study was nested within two surveillance platforms, namely, severe respiratory infection 
(SRI) and influenza-like illness (ILI).  
 
SRI is prospective, hospital-based, sentinel surveillance that was initiated in 2009 and is on-
going. The aim of this surveillance is to investigate the aetiology of pneumonia in South 
Africa. All patients who meet the case definition had specimens taken for laboratory testing. 
The six sites under surveillance are Chris Hani Baragwanath Hospital (Soweto, Gauteng 
province), Edendale Hospital (KwaZulu-Natal province), Mapulaneng and Matikwane 
Hospitals (Mpumalanga province) and the Klerksdorp-Tshepong Hospital complex (North 
West province). Case investigation forms for the SRI surveillance are listed in Appendix 1. In 
2012 the Edendale and the Klerksdorp-Tshepong surveillance sites became enhanced sites.  
 
ILI is a prospective study that began in June 2012 and is aimed to describe the burden and 
aetiology of mild respiratory disease in South Africa in patients of all ages. In addition a 
subset of healthy individuals has also been enrolled to determine colonisation of respiratory 
pathogens. Sites under surveillance are the primary health care clinics, Jouberton that serves 
the Klerksdorp-Tshepong Hospital complex and Edendale Gateway that serves the Edendale 
hospital. Case investigation forms for ILI surveillance are listed in Appendix 2.  
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2. Study Aims and Objectives 
2.1. Aim 
To use two existing surveillance platforms (SRI and ILI) to determine the prevalence of 
respiratory disease caused by the bacterial pathogens B. pertussis, B. parapertussis and 
B. bronchiseptica in paediatric and adult patients presenting with mild or severe respiratory 
tract infections at selected sentinel sites within South Africa from June 2012 to October 2014.  
 
2.2. Objectives 
2.2.1. To implement and validate molecular protocols for the detection of 
B. pertussis, B. parapertussis and B. bronchiseptica 
2.2.2. To determine if macroscopic and Bartlett’s score evaluation influences real 
time PCR results for the detection of B. pertussis and B. parapertussis 
2.2.3. To compare the utility of different specimen types i.e. combined 
nasopharyngeal/oropharyngeal specimens and induced sputum for the detection of 
B. pertussis and B. parapertussis 
2.2.4. To determine if cases positive for B. pertussis differed by demographic 
characteristics based on Ct-value cut-offs (confirmed vs. probable B. pertussis cases) 
2.2.5. To determine if there were any co-infections with respiratory bacteria or 
viruses amongst cases positive for B. pertussis, B. parapertussis and B. bronchiseptica 
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3. Materials and Methods 
3.1. Surveillance population 
Patients hospitalised with severe respiratory illness (SRI) were enrolled in prospective, active 
surveillance conducted at two sentinel sites in South Africa, namely, Edendale hospital in 
Pietermaritzburg, Kwa-Zulu Natal Province, and Klerksdorp-Tshepong hospital Complex in 
Klerksdorp, North West Province, from June 2012 to October 2014. Enrolled patients had to 
meet one of the following criteria: all patients hospitalised with clinical signs and symptoms 
of lower respiratory tract infection (LRTI) irrespective of duration of symptoms; or any child 
(2 days to <3 months old) with diagnosis of suspected sepsis or physician-diagnosed LRTI 
irrespective of signs and symptoms; or any child ≥3 months to <5 years with physician-
diagnosed LRTI including bronchiolitis, pneumonia, bronchitis and pleural effusion and any 
person (≥5 years old) presenting with manifestations of acute lower respiratory infection with 
sudden onset of fever (>38ºC) and cough or sore throat and shortness of breath, or difficulty 
breathing with or without clinical or radiographic findings of pneumonia or tachypnea.  
 
Out-patients with influenza-like illness (ILI) and controls were enrolled at two clinics 
affiliated to the above-mentioned sentinel hospitals during the same study period. A case of 
ILI was defined as an out-patient presenting with acute fever of >38°C and/or self-reported 
fever and cough within the last 7 days, or sore throat and the absence of other diagnoses.  
 
Controls were individuals that presented at the clinics with no history of respiratory illness, 
diarrhoeal illness, or fever in the preceding 14 days. Controls commonly presented to the 
clinic for visits such as dental procedures, family planning, baby clinics, voluntary HIV 
counselling and testing or acute care for non-febrile illnesses. Medical and symptoms history 
were systematically verified by a trained nurse using a structured checklist. One HIV-infected 
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and one HIV-uninfected control were enrolled every week in each out-patient clinic within 
each of the following age categories: 0-1, 2-4, 5-14, 15-54 and ≥55 years.  
 
3.2. Demographic and clinical data collection 
Demographic and clinical data were collected by surveillance officers through interviews and 
hospital record reviews. Data collected included socio-demographic factors, presenting 
symptoms, duration of symptoms and underlying illnesses including HIV and tuberculosis 
exposure and treatment. For all patients, history of influenza immunisations was recorded. In 
addition, for children <5 years, routine immunisation history was documented and confirmed 
from the patients Road-to-Health Card (RTHC). 
 
3.3. Sample collection and transport 
Nasopharyngeal (NP) specimens were collected from all enrolled patients and controls whilst 
induced sputum (IS) was collected from SRI patients only. Nasopharyngeal aspirates were 
obtained from patients <5 years old and combined nasopharyngeal-oropharyngeal swabs were 
collected from patients ≥5 years old. For HIV testing, blood specimens were collected from 
all consenting patients. NP specimens were transported in Universal Transport Medium 
(UTM) (Copan Italia, Brescia, Italy) on ice packs and IS specimens were transported on dry-
ice (Marken Transport, South Africa) to the National Institute for Communicable Diseases 
(NICD) for testing. IS was initially transported at 4°C (June 2012 to June 2013), however, to 
improve specimen quality, transport of IS changed to dry ice from July 2013. 
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3.4. Assessment and processing of induced sputum  
All IS specimens were examined macroscopically and were graded as follows: saliva for a 
clear watery sputum, mucoid for clear sticky sputum, purulent for sputum with pus 
sometimes mixed with mucus and bloody for sputum with blood sometimes mixed with 
mucus/pus. Sputum quality was assessed microscopically by using the Bartlett’s grading 
system on a Gram-stained smear (22). This method was based on analysis of both squamous 
epithelial cells and neutrophils. Good quality sputum was expected to have a higher number 
of neutrophils which are indicative of inflammation as opposed to squamous epithelial cells 
which are indicative of saliva (22). A Bartlett’s score of 1 indicates the presence of between 
10 – 25 neutrophils and a score of 2 indicates the presence of >25 neutrophils. In addition a   
 -1 score indicates the presence of between 10 – 25 epithelial cells and a -2 score indicates the 
presence of >25 epithelial cells. Good quality sputum was expected to have a positive 
Bartlett’s score and should not be saliva; however, no sputum specimens were rejected based 
on poor macroscopic or microscopic evaluations. 
 
In addition, specimens were plated onto charcoal agar for Bordetella (Diagnostic Media 
Products, Johannesburg, South Africa) for culture. All plates were incubated at 35-37°C for 
10 days before being inspected for possible colonies (52). 
 
IS was then digested and decontaminated with a 1:10 dilution of dithiothreitol (DTT) (Roche 
Diagnostics, Mannheim, Germany) (53). Sputum volume was measured and an equal volume 
of DTT was added. The mixture was vortexed for 30 seconds and then incubated at 37°C for 
15 minutes. Phosphate buffered saline (Diagnostic Media Products, Johannesburg, South 
Africa) at a pH of 7.2 was added to remove any excess DTT. Samples were centrifuged at 
2000 rpm for 5 minutes and stored at 4°C until DNA extraction.  
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3.5. DNA extraction 
NP specimens in UTM and digested IS specimens underwent an automated DNA extraction 
using the Roche MagNa Pure 96 instrument (Roche Diagnostics, Mannheim, Germany) and 
MagNa Pure 96 DNA and Viral NA SV Kit (Roche Diagnostics) and the Pathogen Universal 
Protocol. DNA was extracted from a 200µl aliquot of sample, eluted into 100µl of elution 
buffer and stored at -20°C until further testing. 
 
3.6. Real-time PCR  
Detection of B. pertussis, B. parapertussis, B. holmesii and B. bronchiseptica were performed 
using previously-published real-time PCR assays (26;27). The multiplex assay detects IS481 
to determine the presence of Bordetella spp. (B. pertussis, B. bronchiseptica and B. holmesii), 
pIS1001 for B. parapertussis, and hIS1001 for B. holmesii. The second assay is a singleplex 
which confirms B. pertussis, B. bronchiseptica and B. parapertussis by detecting the ptxS1 
toxin gene (Appendix 3). All reactions were carried out in an Applied Biosystems 7500 Fast 
instrument (Applied Biosystems, Foster City, California, USA) using universal cycling 
conditions. The reaction volume was 25µl, and consisted of TaqMan Gene Expression master 
mix, (Applied Biosystems, Foster City, California, USA), 4µl of extracted DNA and primers 
and probes as previously described (Appendix 3). 
 
A positive PCR result was recorded if a Ct-value of ≤45 for any of the gene targets was 
obtained. All specimens that tested positive for any gene target were re-extracted and tested 
in duplicate to confirm the result. A specimen was confirmed as positive if it was positive on 
2/3 or 3/3 repeats. For B. pertussis, results were interpreted according to the published 
algorithm (26;27), with minor modifications (Appendix 5): If a specimen tested positive for 
IS481 with a Ct-value <35, irrespective of ptxS1, then this specimen was recorded as 
Page 32 of 104 
 
confirmed positive. If a specimen tested positive for IS481 with a Ct-value ≥35, irrespective 
of ptxS1, then this specimen was defined as probable positive for B. pertussis. For 
B. parapertussis, cases were not classified into confirmed or probable based on Ct-value cut-
off’s. If a specimen tested positive for pIS1001 (Ct-value of ≤45), irrespective of the ptxS1, 
then this specimen was defined as positive for B. parapertussis.  
 
Detection of the human ribonuclease P (RNase P) gene was performed and served as an 
internal control to identify the presence of potential PCR inhibitors, and/or confirm DNA 
quality (54). Results of the RNase P assay were used to interpret PCR negative results i.e. 
samples that also tested RNase P negative were interpreted as possible false negatives due to 
the presence of inhibitors or poor DNA quality in the clinical sample.  
 
3.6.1. Validation of real-time PCR 
The following steps were followed to validate the PCR assays:  
PCR sensitivity and specificity was determined using Bordetella spp. controls from the 
American Type Culture Collection (ATCC) (Appendix 4) diluted to 10
-3
. Results were 
interpreted according to the modified algorithm. 
 
PCR robustness was determined by testing two PCR master mixes, namely, TaqMan Gene 
Expression master mix (Applied Biosystems) and PerfeCTa Multiplex qPCR super mix 
(Quanta Biosciences, Gaitherburg, MD, US). B. pertussis ATCC 9797-D DNA control was 
serially diluted from 10
-1
 to 10
-9
 and assays were performed in duplicate. 
 
External proficiency testing for the B. pertussis assays was performed through Quality 
Control for Molecular Diagnostics (QCMD) (Glasgow, Scotland) which is proficiency testing 
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programme that assesses molecular detection methodologies (www.qcmd.org). Each year the 
panel of interest consists of 5 core and 7 education samples. The 2011 and 2012 panel was 
given to us by the NHLS Infection Control laboratory. From 2013 onwards we subscribed to 
this programme (Appendix 6). Each DNA extract from the panel was run in triplicate and 
results were interpreted according to the modified algorithm. Results from the 2011, 2012, 
2013 and 2014 panel were also used to calculate the sensitivity and specificity of the PCR 
assays. 
 
3.7. Determination of HIV status 
HIV results were determined from either the patient’s clinical record if available and/or an 
anonymised linked dried blood spot. For patients <18 months PCR was performed and for 
patients ≥18 months the enzyme-linked immunosorbent assay was performed. HIV status was 
determined at the NICD HIV laboratory.  
 
3.8.  Co-infections 
Additional tests were carried out on all NP, IS and blood specimens that were received at the 
NICD as part of the SRI and ILI projects. NPs were tested by the CRDM virology laboratory 
for 10 respiratory viruses (influenza types A and B, adenovirus, enterovirus, rhinovirus, 
human metapneumovirus, respiratory syncytial virus (RSV) and parainfluenza virus types 1-
3); NP and IS specimens were tested for M. pneumoniae, C. pneumoniae and Legionella spp. 
(54) and blood specimens were tested for S. pneumoniae (55) and H. influenzae (56) as part 
of routine testing at CRDM bacteriology laboratory. Only SRI cases were analysed for co-
infections. 
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3.9. Data analysis 
Patient demographics, clinical, epidemiological (including vaccine history, age, gender, 
symptoms, duration of symptoms, HIV status, administration of antibiotics before hospital 
admission, duration of hospital stay, area of residence) and laboratory results were entered in 
a Microsoft Access database (Microsoft Corporation, California, USA) in a double-data entry 
format.  
 
The sensitivity and specificity of the real-time PCR assays were determined using the 
following equations: 
Sensitivity = number of true positives / (number of true positives + number of false 
negatives) 
Specificity = number of true negatives / (number of true negatives + number of false 
positives) 
 
IS specimens that had a macroscopic and/or Bartlett’s score results available were evaluated 
to determine if either of these characteristics influenced the overall result obtained by real-
time PCR for the detection of B. pertussis and B. parapertussis. 
 
To determine which of the specimen types were most ideal for the detection of B. pertussis 
and B. parapertussis, patients enrolled into the SRI surveillance population that had both an 
NP and an IS specimen taken for testing were analysed. Patient characteristics amongst the 
positive patients were also evaluated to determine if patient characteristics differed by 
specimen type taken for testing. Analysis was performed on cases that had only 1 of the 2 
specimen types test positive on the real-time PCR. Cases that had both specimens types test 
positive were excluded for this analysis.  
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Confirmed and probable B. pertussis cases as well as B. parapertussis-positive and 
B. parapertussis-negative cases were compared amongst the SRI and ILI surveillance 
populations using patient characteristics. Cases for this analysis were defined as having either 
or both specimen types test positive on real-time PCR. Ct-values amongst the confirmed and 
probable B. pertussis cases were analysed.  
 
Using the control group as the reference group and controlling for HIV status and age group; 
the attributable fraction of disease of B. pertussis and B. parapertussis between cases 
presenting with SRI, ILI were calculated using the following equation: 
Attributable fraction = (odds ratio-1) / (odds ratio*100) 
For this analysis a positive case was defined as having either or both specimen types positive 
by real-time PCR. 
 
SRI cases that tested positive for any Bordetella spp. were analysed to determine if they were 
co-infected with either respiratory bacteria or viruses. A positive co-infected case was 
defined as having a real-time PCR positive result for any respiratory bacteria or virus 
mentioned in 3.9. 
 
All data were analysed in Microsoft Excel (Microsoft Corporation). The chi-squared test was 
used for the analysis of categorical variables and the Kolmogorov-Smirnov test was used for 
the analysis of continuous variables. Univariate logistic regression was used to determine 
odds ratios (OR) and 95% confidence intervals .For the analysis of continuous variables 
statistical significance was determined at p<0.05. Statistical significance was obtained using 
Graph Pad Instat software (version 3.10, California, USA) and Stata
®
 version 12 (Statacorp, 
College Station, TX).   
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3.10. Ethics 
The SRI protocol (M081042) was approved by the Human Research Ethics Committee-
Medical (HREC) of the University of the Witwatersrand (Wits), Johannesburg and includes 
ethics clearance for the Klerksdorp-Tshepong surveillance sites. An amended SRI and ILI 
protocol was approved by the HREC of the University of the Witwatersrand which includes 
approval for work proposed in this study. For the Edendale surveillance site, ethics has been 
approved by the Kwa-Zulu Natal provincial ethics committee. Ethics for the MSc project was 
approved by Wits HREC (M130260) (Appendix 7).  
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4. Results 
4.1. Validation of real-time PCR 
ATCC controls B. pertussis, B. parapertussis, B. bronchiseptica and B. holmesii were 
correctly identified as such and a negative PCR result was obtained for B. avium, B. hinzii, 
and B. petrii. PCR sensitivity and specificity were calculated using the results obtained from 
the ATCC controls and the 2011, 2012, 2013 and 2014 QCMD panels. The PCR was 95% 
(20/21) sensitive and 100% (31/31) specific for B. pertussis. A 100% sensitivity and 100% 
specificity was obtained for B. parapertussis (sensitivity 5/5 and specificity 48/48), 
B. bronchiseptica (sensitivity 9/9 and specificity 44/44) and B. holmesii (sensitivity 5/5 and 
specificity 48/48), respectively.  
 
The mean Ct obtained for each of the dilutions tested for IS481 using the Taqman Gene 
Expression master mix and the Quanta super mix are listed in Table 1. PCR performed using 
the TaqMan Gene Expression master mix (Applied Biosystems) yielded lower Ct-values (±2 
Ct difference) for each of the dilutions when compared to the Ct-values obtained using the 
Quanta super mix although this was not statistically significant (p=0.09). 
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Table 1: Comparison of Ct-values of IS481 obtained by performing real-time PCR using the 
Taqman Gene Expression mastermix and the Quanta super mix. 
ATCC 9797-D B. 
pertussis dilution 
IS481 Ct (Taqman Gene 
Expression master mix)
1
 
IS481 Ct (Quanta 
super mix)
2
 
B. pertussis neat 6 11 
B. pertussis 10 
-1
 10 14 
B. pertussis 10 
-2
 13 17 
B. pertussis 10 
-3
 17 20 
B. pertussis 10 
-4
 20 23 
B. pertussis 10 
-5
 24 26 
B. pertussis 10 
-6
 28 29 
B. pertussis 10 
-7
 32 33 
B. pertussis 10 
-8
 35 36 
B. pertussis 10 
-9
 41 44
3
 
B. pertussis 10 
-10
 Negative Negative 
B. pertussis 10 
-11
 Negative Negative 
B. pertussis 10 
-12
 Negative Negative 
B. pertussis 10 
-13
 Negative Negative 
B. pertussis 10 
-14
 Negative Negative 
B. pertussis 10 
-15
 Negative Negative 
p-value 0.09 
1, 2
: Each dilution of the B. pertussis DNA extract was run in duplicate. The mean Ct of each dilution was used 
in above table. 
3: 
Only 1 of the duplicates tested positive at this dilution. 
 
All samples from the 2011, 2013 and 2014 QCMD panels were correctly resulted. For the 
2012 panel, 1 DNA extract was a known positive for B. pertussis but a negative result was 
obtained in this study. The specimen was re-tested but the result remained negative. Ct-values 
for the B. pertussis positive samples ranged from 34 to 42, however no Ct-values were sent 
back from QCMD with result reports so no comparisons could be made.  
 
4.2. Surveillance population 
From June 2012 to October 2014, 9684 cases were enrolled into the SRI, ILI and controls 
surveillance programs. Of the 9684 cases enrolled, 8569 cases had specimens taken for 
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testing of which 3982, 3243 and 1344 were from SRI, ILI and control individuals, 
respectively (Figure 2). There were 9684 cases enrolled but only 8569 cases had specimens 
taken for testing. This difference was due to one of the following reasons: patients enrolled 
did not give consent to take specimens; patients enrolled within the SRI surveillance were too 
sick to have specimens taken or could not have both a NP and IS taken; patients were 
discharged before specimens could be taken; or specimens were lost in transit or were 
insufficient for testing.  
 
Figure 2: Flow diagram depicting the cases enrolled for SRI, ILI and controls surveillance 
groups as well as the specimen type received for laboratory testing, South Africa, June 2012 
– October 2014. 
 
Specimens from 8569 cases were collected and tested using the Bordetella spp. real-time 
PCR of which 3982 (46%, 3982/8569) were from SRI cases, 3243 (38%, 3243/8569) were 
from ILI cases and 1344 (16%, 1344/8569) were from controls (Table 2). Of the SRI and ILI 
cases, 55% (1896/3452) and 30% (855/2809) were HIV positive, respectively. Within the 
SRI and ILI surveillance groups, the 25-44 year age group had the highest numbers of cases 
8569 cases tested with 
specimens  
3982 (46%) SRI cases 
 
 3982 NP specimens 
 1980 IS 
 
3243 (38%) ILI cases 
 
3243 NP specimens 
only 
 
1344 (16%) controls 
 
1344 NP specimens 
only  
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enrolled and tested [(33%, 1301/3973) and (30%, 971/3242) respectively], and the majority 
of the population was black.  
 
Table 2: Demographic and clinical characteristics of patients enrolled into the severe 
respiratory and influenza-like illness surveillance that were tested for Bordetella species, 
South Africa, June 2012 – October 2014 (N=8569). 
Characteristic 
Surveillance population 
SRI n/N (%) 
N=3982 
ILI n/N (%) 
N=3243 
Controls n/N (%) 
N=1344) 
Gender 
  
    Male 2013/3975 (51) 1164/3195 (36) 453/1317 (34) 
   Female 1962/3975 (49) 2031/3195 (64) 864/1317 (66) 
Race 
   
   Black 3884/3975 (98) 3192/3195 (100) 1317/1317 (100) 
   Non-black 91/3975 (2) 3/3195 (0.1) 0 
Age group (years) 
   
   <1 880/3973 (22) 303/3242 (9) 169/1343 (13) 
   1-4 497/3973 (13) 614/3242 (19) 303/1343 (23) 
   5-14 116/3973 (3) 514/3242 (16) 280/1343 (21) 
   15-24 208/3973 (5) 453/3242 (14) 93/1343 (7) 
   25-44 1301/3973 (33) 971/3242 (30) 203/1343 (15) 
   45-64 761/3973 (19) 333/3242 (10) 209/1343 (16) 
   ≥65 210/3973 (5) 54/3242 (2) 86/1343 (6) 
Underlying illness
1
 
   
   No 3536/3973 (89) 3021/3185 (95) 1243/1313 (95) 
   Yes 437/3973 (11) 164/3185 (5) 70/1313 (5) 
HIV status 
   
   Uninfected 1556/3452 (45) 1954/2809 (70) 700/1246 (56) 
   Infected 1896/3452 (55) 855/2809 (30) 546/1246 (44) 
Clinic/Hospital 
   
   Edendale 1770/3982 (44) N/A  N/A 
   Edendale Gateway N/A 2385/3243 (74) 521/1344 (39) 
   Jouberton Clinic  N/A 858/3243 (26) 823/1344 (61) 
   KTHC 2212/3982 (56)    N/A 
Abbreviations SRI=Severe respiratory illness; ILI=Influenza-like illness; KTHC=Klerksdorp-Tshepong hospital 
complex; N/A=Not applicable. 
1
Patients with previously diagnosed chronic conditions including asthma, chronic lung diseases, cirrhosis/liver 
failure, chronic renal failure, heart failure, valvular heart disease, coronary heart disease, immunosuppressive 
therapy, splenectomy, diabetes, burns, kwashiorkor/marasmus, nephrotic syndrome, spinal cord injury, seizure 
disorder, emphysema, or cancer. All percentages rounded off.
Page 41 of 104 
 
4.3. B. pertussis 
4.3.1. Specimen quality and comparison of specimen types for the detection of 
B. pertussis 
Of the 1980 IS specimens collected from SRI patients, the macroscopic evaluation was 
performed on 1615 (82%, 1615/1980) specimens and the Bartlett’s score evaluation was 
performed on 1088 specimens (55%, 1088/1980) that were tested using the Bordetella spp. 
real-time PCR assays. It was observed that 35% (8/23) of the B. pertussis positive cases were 
mucoid/purulent and 44% (4/9) of the cases had a positive Bartlett’s score (Table 3). All 1980 
IS specimens were culture negative for B. pertussis.  
 
Table 3: Macroscopic (N=1615) and Bartlett’s score (N=1088) evaluation of induced sputum 
collected from SRI patients, by B. pertussis PCR result, South Africa, June 2012 – October 
2014 (N=2703). 
Characteristic 
B. pertussis positive  B. pertussis negative 
Total  
n/N (%)  n/N (%) 
Macroscopic evaluation 
      Saliva 5/23 (22) 457/1592 (29)  
   Mucoid 8/23 (35) 625/1592 (39)  
   Purulent 8/23 (35) 347/1592 (22)  
   Blood stained 2/23 (9) 163/1592 (10)  
Total 23 1592 1615 
Bartlett’s score 
  
 
   Negative 2/9 (22) 343/1079 (32)  
   0 3/9 (33) 287/1079 (27)  
   Positive 4/9 (44) 449/1079 (42)  
Total 9 1079  1088 
Negative (combined -1 and -2 score) = presence of between 10 – 25 (-1) and >25 (-2) epithelial cells.  
0= presence of <10 neutrophils. 
Positive= (combined +1 and +2 score) = presence of between 10 – 25 (+1) and >25 (+2) neutrophils. 
Good quality sputum should have a positive Bartlett’s score and should not be saliva. 
All percentages rounded off. 
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There were 1778 SRI cases that had both an NP and an IS specimen taken for testing. The 
detection rate of B. pertussis was lower in NP specimens compared to IS specimens [8/1726, 
0.5% vs. 31/1726, 1.8%, p=0.005]. The detection rate in cases with both specimen types was 
0.75% (13/1726). Cases positive for B. pertussis that had both an NP and IS specimen taken 
for testing were then stratified by specimen type and patient demographics, however no 
differences were observed (Table 4).  
 
Table 4: Comparison of nasopharyngeal and induced sputum B. pertussis positive specimens 
from cases presenting with severe respiratory illness in South Africa, South Africa, June 2012 
– October 2014 (N=39). 
Characteristic 
B. pertussis PCR result   
NP B. pertussis positive 
n/N (%) 
IS B. pertussis positive 
n/N (%) 
OR (95% CI) 
Year 
  
 
   2012 4/5 (80) 1/5 (20) reference 
   2013 4/12 (33) 8/12 (68) 8 (0.7 – 97) 
   2014 0 22/22 (100) N/A 
Positive category    
   Confirmed pertussis 2/5 (40) 3/5 (60) reference 
   Probable pertussis 6/34 (18) 28/34 (82) 3 (0.4 – 23) 
Gender    
   Female 3/16 (19) 13/16 (81) reference 
   Male  5/23 (22) 18/23 (78) 0.8 (0.2 – 4) 
Age group (year)    
   <1  0 2/2 (100) reference 
   1-4 1/4 (25) 3/4 (75) N/A 
   5-14 0 0  N/A 
   15-24 0 1/1 (100) N/A 
   25-44 5/16 (31) 11/16 (69) N/A 
   45-64 2/12 (17) 10/12 (83) N/A 
   ≥65 0 4/4 (100) N/A 
Fever history    
   No 6/28 (21) 22/28 (79) reference 
   Yes 2/10 (20) 8/10 (80) 1 (0.2 – 7) 
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HIV status    
   Uninfected 3/13 (23) 10/13 (77) reference 
   Infected 2/23 (9) 21/23 (91) 3 (0.5 – 22) 
HIV treatment    
   No 2/9 (22) 7/9 (78) reference 
   Yes 3/14 (21) 11/14 (79) 1 (0.1 – 8) 
Symptom duration    
   <7 days 3/16 (19) 13/16 (81) reference 
   7-20 days 3/9 (33) 6/9 (67) 0.5 (0.07 – 3) 
   ≥21 days 1/13 (8) 12/13 (92) 3 (0.3 – 30) 
Underlying illness
1
    
   No 7/33 (21) 26/33 (79) reference 
   Yes 1/6 (17) 5/6 (83) 1 (0.1 – 13) 
ICU    
   No 8/39 (21) 31/39 (79) 
N/A 
   Yes 0 0 
Antibiotic treatment 
(24 hours)    
 
   No 8/39 (21) 31/39 (79) 
N/A  
   Yes 0 0 
Hospital duration    
   <2 days 1/6 (17) 5/6 (83) reference 
   2-4 days 3/14 (21) 11/14 (79) 0.7 (0.06 – 9) 
   5-7 days 2/8 (25) 6/8 (75) 0.6 (0.04 – 9) 
   ≥8 days 2/11 (18) 9/11 (82) 0.9 (0.06 – 13) 
Viral co-infection    
   No 6/27 (22) 21/27 (78) reference 
   Yes 2/12 (17) 10/12 (83) 1 (0.2 – 8) 
Outcome    
   Survived 6/32 (19) 26/32 (81) reference 
   Died 2/7 (29) 5/7 (71) 0.6 (0.09 – 4) 
Vaccination for age
2
    
   Full coverage 1/4 (25) 3/4 (75) 
N/A  
   Incomplete coverage 0 2/2 (100) 
Facility    
   Edendale 4/12 (33) 8/12 (67) reference 
   KTHC 4/27 (15) 23/27 (85) 3 (0.6 – 14) 
Abbreviations: NP=nasopharyngeal; IS=induced sputum; KTHC=Klerksdorp-Tshepong hospital complex; 
N/A=not applicable, OR= Odd ratio; CI=Confidence interval 
1
Patients with previously diagnosed chronic conditions including asthma, chronic lung diseases, cirrhosis/liver 
failure, chronic renal failure, heart failure, valvular heart disease, coronary heart disease, immunosuppressive 
therapy, splenectomy, diabetes, burns, kwashiorkor/marasmus, nephrotic syndrome, spinal cord injury, seizure 
disorder, emphysema, or cancer. 
2
Only for children ≤5 years of age where vaccine history was available on the road-to-health card. 
Confirmed positive=positive for B. pertussis if IS481 Ct <35; Probable positive=positive for B. pertussis if 
IS481 Ct ≥35. All percentages rounded off. 
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4.3.2. Comparison of B. pertussis positive cases (confirmed pertussis vs. 
probable pertussis) by surveillance group  
Confirmed and probable B. pertussis positives were observed in both NP and IS specimens 
(Figures 3 and 4). The mean Ct-value (±standard deviation) for confirmed B. pertussis 
positive NP and IS specimens was 34±5 and 25±6 respectively, and the mean Ct for probable 
B. pertussis positive NP and IS specimens was 36±5 and 39±2 respectively.  
 
There were 82 [2%, 82/3982 (95% CI 1.6 – 2.5)] NP specimens that tested positive for B. 
pertussis of which 35 were confirmed and 47 were probable pertussis positives. Of the 
confirmed pertussis positives, 94% (33/35) were positive for both IS481 and ptxS1 and for the 
probable pertussis cases, only 19% (9/47) were positive on both gene targets.  
 
From 49 [2.5%, 49/1980 (95% CI 1.8 – 3.3)] IS specimens positive for B. pertussis, 16 
(100%, 16/16) confirmed cases and 12% (4/33) of probable cases were positive on both gene 
targets, respectively.  
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Figure 3: IS481 Ct-value distribution of B. pertussis confirmed (n=35) and probable (n=47) results from nasopharyngeal specimens, South 
Africa, June 2012 – October 2014 (N=82). 
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Figure 4: IS481 Ct-value distribution of B. pertussis confirmed (n=16) and probable (n=33) results from induced sputum specimens, South 
Africa, June 2012 – October 2014 (N=49).
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Table 5: Comparison of confirmed and probable B. pertussis cases in patients presenting with 
severe respiratory illness, South Africa, June 2012 – October 2014 (N=3982). 
Characteristic 
 B. pertussis PCR result 
Confirmed n/N 
(%) 
Probable n/N 
(%) 
OR
3
 
(95% CI) 
Negative n/N (%) 
Year 
  
 
    2012 7/18 (39) 11/39 (61) reference 1152/3902 (30) 
   2013 9/25 (36) 16/25 (64) 1 (0.3 – 4) 1624/3902 (42) 
   2014 13/37 (35) 24/37 (65) 1 (0.4 – 4) 1126/3902 (29) 
Gender 
  
 
 
   Female 19/43 (44) 24/43 (56) reference 1919/3895 (49) 
   Male  10/37 (27) 27/37 (73) 2 (0.8 – 5) 1976/3895 (51) 
Age group 
  
 
    <1 10/19 (53) 9/19 (47) reference 861/3893 (22) 
   1-4 3/8 (38) 5/8 (63) 2 (0.3 – 10) 489/3893 (13) 
   5-14 1/1 (100) 0 NA 115/3893 (3) 
   15-24 0 2/2 (100) NA 206/3893 (5) 
   25-44 12/25 (48) 13/25 (52) 1 (0.4 – 4) 1276/3893 (33) 
   45-64 1/19 (5) 18/19 (95) 20 (2 – 182) 742/3893 (19) 
   ≥65 2/6 (33) 4/6 (67) 2 (0.3 – 15) 204/3893 (5) 
Fever history 
  
 
    No 19/52 (37) 33/52 (63) reference 2095/3870 (54) 
   Yes 9/27 (33) 18/27 (67) 1 (0.4 – 3) 1775/3870 (46) 
HIV status 
  
 
    Uninfected 8/30 (27) 22/30 (73) reference 1526/3385 (45) 
   Infected 13/37 (35) 24/37 (65) 0.7 (0.2 – 2) 1859/3385 (55) 
HIV treatment 
  
 
    No 5/15 (33) 10/15 (67) reference 703/1588 (44) 
   Yes 6/20 (30) 14/20 (70) 1 (0.3 – 5) 885/1588 (56) 
Symptom 
duration 
  
 
    <7 days 19/41 (46) 22/41 (54) reference 2090/3824 (55) 
   7-20 days 4/13 (31) 9/13 (69) 2 (0.5 – 7) 818/3824 (21) 
   ≥21 days 6/23 (26) 17/23 (74) 2 (0.8 – 7) 916/3824 (24) 
Underlying illness
1
 
  
 
    No 27/69 (39) 42/69 (61) reference 3467/3893 (89) 
   Yes 2/11 (18) 9/11 (82) 3 (0.6 – 14) 426/3893 (11) 
ICU 
  
 
    No 28/77 (36) 49/77 (64) reference 3755/3811 (99) 
   Yes 11/2 (50) 1/2 (50) 0.6 (0.03 – 9) 56/3811 (1) 
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Antibiotic treatment 
(24 hours)  
  
 
    No 28/77 (36) 49/77 (64) reference 3694/3878 (95) 
   Yes 1/3 (33) 2/3 (67) 1 (0.1 – 13) 184/3878 (5) 
Hospital duration 
  
 
    <2 days 3/11 (27) 8/11 (73) reference 385/3646 (11) 
   2-4 days 9/28 (32) 19/28 (68) 0.8 (0.2 – 4) 1073/3646 (29) 
   5-7 days 2/12 (17) 10/12 (83) 2 (0.2 – 14) 953/3646 (26) 
   ≥8 days 12/26 (46) 14/26 (54) 0.4 (0.09 – 2) 1235/3646 (34) 
Viral co-infection 
  
 
    No 13/46 (28) 33/46 (72) reference 2120/3872 (55) 
   Yes 16/34 (47) 18/34 (53) 0.4 (0.2 – 1) 1752/3872 (45) 
Outcome 
  
 
    Survived 26/71 (37) 45/71 (63) reference 3445/3775 (91) 
   Died 2/8 (25) 6/8 (75) 2 (0.3 – 9) 330/3775 (9) 
Vaccination for age
2
 
  
 
    Full coverage 3/12 (25) 9/12 (75) reference 942/1165 (81) 
   Incomplete  5/9 (56) 4/9 (44) 4 (0.6 – 24) 223/1165 (19) 
Facility 
  
 
    Edendale 13/31 (42) 18/31 (58) reference 1739/3902 (45) 
   KTHC 16/49 (33) 33/49 (67) 1 (0.6 – 4) 2163/3902 (55) 
Abbreviations: KTHC=Klerksdorp-Tshepong hospital complex, NA – not applicable; OR=Odds ratio; 
CI=Confidence interval. 
1
Patients with previously diagnosed chronic conditions including asthma, chronic lung diseases, cirrhosis/liver 
failure, chronic renal failure, heart failure, valvular heart disease, coronary heart disease, immunosuppressive 
therapy, splenectomy, diabetes, burns, kwashiorkor/marasmus, nephrotic syndrome, spinal cord injury, seizure 
disorder, emphysema, or cancer. 
2only for children ≤5 years of age where vaccine history was available on the road-to-health card 
Confirmed positive=positive for B. pertussis if IS481 Ct <35; Probable positive=positive for B. pertussis if 
IS481 Ct ≥35. All percentages rounded off. 3Bold font indicates statistical significance. 
 
B. pertussis confirmed and probable cases differed by age group only (Table 5). The 
detection rate of probable cases was significantly higher than the detection rate of the 
confirmed cases in the 45-64 year olds when compared to the <1 year olds [OR=20 (95% CI 
2 – 182)]. HIV status and full pertussis vaccination for age did not influence the confirmed 
pertussis and probable pertussis cases. Overall, the highest detection rate was observed in the 
≥65 year age group (2.8%, 6/208) (Figure 5). The detection rate in the <1 year age group was 
2.2% (19/880). We stratified this age group into <3 months and ≥4 months. The detection rate 
in the <3 months age group was 2.1% (8/374) and 2.2% (11/506) in the ≥4 months (p=1.00). 
None of the infants in this age group died.
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Figure 5: Detection rate of B. pertussis (confirmed vs. probable) cases by age group in cases presenting with severe respiratory illness, South 
Africa, June 2012 – October 2014 (N=3973).
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Table 6: Comparison of confirmed and probable B. pertussis cases in patients presenting with 
influenza-like illness, South Africa, June 2012 – October 2014 (N=3243). 
Characteristic 
 B. pertussis PCR result ILI cases 
Confirmed  
n/N (%) 
Probable  
n/N (%) 
OR  
(95% CI)
3
 
Negative n/N 
(%) 
Year 
  
 
    2012 4/10 (40) 6/10 (60) reference 960/3211 (30) 
   2013 3/5 (60) 2/5 (40) 0.4 (0.05 – 4) 851/3211 (27) 
   2014 8/17 (47) 9/17 (53) 0.8 (0.2 – 4) 1400/3211 (44) 
Gender 
  
 
 
   Female 10/19 (53) 9/19 (47) reference 2012/3165 (64) 
   Male  5/11 (45) 6/11 (55) 1 (0.3 – 6) 1153/3165 (36) 
Age group 
  
 
    <1 1/1 (100) 0 reference 302/3210 (10) 
   1-4 2/9 (22) 7/9 (78) N/A 605/3210 (19) 
   5-14 3/6 (50) 3/6 (50) N/A 508/3210 (16) 
   15-24 2/6 (33) 4/6 (67) N/A 447/3210 (14) 
   25-44 7/10 (70) 3/10 (30) N/A 961/3210 (30) 
   45-64 0 0 N/A 333/3210 (10) 
   ≥65 0 0 N/A 54/3210 (2) 
Fever history 
  
 
    No 1/5 (20) 4/5 (80) reference 125/3159 (4) 
   Yes 14/25 (56) 11/25 (44) 0.2 (0.02 – 2) 3034/3159 (96) 
HIV status 
  
 
    Uninfected 4/14 (29) 10/14 (71) reference 1940/2784 (70) 
   Infected 7/11 (64) 4/11 (36) 0.2 (0.04 – 1) 844/2784 (30) 
HIV treatment 
  
 
    No 2/5 (40) 3/5 (60) reference 318/823 (39) 
   Yes 5/6 (83) 1/6 (17) 0.1 (0.008 – 2) 505/823 (61) 
Symptom duration 
  
 
    <7 days 13/25 (52) 12/25 (48) reference 177/3080 (6) 
   7-20 days 2/3 (67) 1/3 (33) 0.5 (0.04 – 7) 66/3080 (2) 
   ≥21 days 0 1/1 (100) N/A 2837/3080 (92) 
Underlying illness
1
 
  
 
    No 14/28 (50) 14/28 (50) reference 2993/3155 (95) 
   Yes 1/2 (50) 1/2 (50) 1 (0.06 – 18) 162/3155 (5) 
Viral co-infection 
  
 
    No 9/20 (45) 11/20 (55) reference 1692/3194 (53) 
   Yes 6/10 (60) 4/10 (40) 0.5 (0.1 – 3) 1502/3194 (47) 
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Vaccination 
  
 
    Full coverage
2
 2/4 (50) 2/4 (50) 
N/A 
695/800 (87) 
   Incomplete  0 2/2 (100) 105/800 (13) 
Facility 
  
 
    Edendale Gateway 10/13 (77) 3/13 (23) reference 2372/3211 (74) 
   Jouberton 5/19 (26) 14/19 (74) 0.1 (0.02 – 0.6) 839/3211 (26) 
Abbreviations: NA=not applicable; OR=Odds ratio; CI=Statistical significance. 
1
Patients with previously diagnosed chronic conditions including asthma, chronic lung diseases, cirrhosis/liver 
failure, chronic renal failure, heart failure, valvular heart disease, coronary heart disease, immunosuppressive 
therapy, splenectomy, diabetes, burns, kwashiorkor/marasmus, nephrotic syndrome, spinal cord injury, seizure 
disorder, emphysema, or cancer. 
2
only for children ≤5 years of age where vaccine history was available on the road-to-health card 
Confirmed positive=positive for B. pertussis if IS481 Ct <35; Probable positive=positive for B. pertussis if 
IS481 Ct ≥35. 
3
Bold font indicates statistical significance. All percentages rounded off. 
 
When comparing confirmed to probable pertussis in ILI cases, confirmed cases were 
significantly less likely to be detected at Jouberton when compared to Edendale Gateway 
[OR=0.1 (95% CI 0.02 – 0.6)] (Table 6). The highest detection rate for ILI cases positive for 
B. pertussis was in the 1-4 year age group [1.5% (9/614)] (Figure 6). There was only 1 
confirmed pertussis case in the <1 year age group and this patient was 3 months of age. There 
were no fatalities in this age group. 
 
There were 6 control individuals that tested positive for B. pertussis. Three of the cases were 
confirmed pertussis and 3 were probable pertussis. The ages of the positive cases varied 
between 5 and 44 years. Eighty three percent (5/6) of these individuals were HIV infected.
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Figure 6: Detection rate of B. pertussis (confirmed vs. probable) cases by age group in cases presenting with influenza-like illness, South Africa, 
June 2012 – October 2014 (N=3242).  
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4.3.3. Attributable fraction of B. pertussis disease  
Table 7: Attributable fraction of B. pertussis disease in cases with severe respiratory illness and influenza-like illness, South Africa, June 2012 – 
October 2014 (N=8569). 
Surveillance group 
Cases 
tested 
Cases 
positive 
Detection rate 
(%) 
Odds ratio (95% CI) Attributable fraction (95% CI) 
SRI – Overall positives1 3982 80 2.0% 3.03 (1.23 – 7.48) 66.99 (18.49 – 86.63) 
SRI – Confirmed positives2 3982 29 0.7% 3.21 (0.85 – 12.14) 68.83 (-17.94 – 91.76) 
ILI – Overall positives1 3243 32 1.0% 2.11 (0.81 – 5.52) 52.68 (-23.77 – 81.90) 
ILI – Confirmed positives2 3243 15 0.5% 1.77 (0.44 – 7.06) 43.40 (-126 – 85.84) 
Controls 1344 6 0.4% reference reference 
Abbreviations: SRI=Severe respiratory illness; ILI=Influenza-like illness; CI=Confidence interval. 
Attributable fraction calculated for SRI cases using positive nasopharyngeal and induced sputum positive specimens. 
1
Overall positives are all cases that tested positive for B. pertussis within the surveillance group. 
2
Confirmed positive=positive for B. pertussis if IS481 Ct <35. 
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The B. pertussis attributable fraction was 67% (95% confidence interval [CI] 18.49 – 86.63) 
after adjusting for HIV status and age group (Table 7). This result indicates that 67% of 
B. pertussis SRI cases could be attributed to B. pertussis infection. When this analysis was 
restricted to B. pertussis confirmed SRI cases the attributable risk was not statistically 
significant.  
 
4.3.4. Seasonality of B. pertussis disease 
B. pertussis showed some periodicity during the surveillance period with peaks of disease 
observed in late winter and early spring (July – September) (Figure 7). The overall detection 
rate for 2013 was 1.5% (25/1624) and for 2014 this rate increased to 3.2% (37/1126) 
(p=0.005). The highest detection rate for B. pertussis was observed in August 2014 (15.4%, 
21/136). This increase in positive cases was observed only at the Jouberton clinic and 
Tshepong hospital (only data from Tshepong hospital (SRI cases) included in Figure 7). The 
increase was investigated to determine if it was a true reflection of disease or due to 
laboratory or environmental contamination. An evaluation of all laboratory control measures 
and testing of environmental samples from the Jouberton and Tshepong facilities excluded 
facility and laboratory contamination and indicated a true increase in B. pertussis infection. 
The increase in disease was not sustained and the detection rate of B. pertussis decreased 
from September 2014.
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Figure 7: Seasonality of B. pertussis in cases presenting with severe respiratory illness, by month and year, South Africa, June 2012 – October 
2014 (N=3982). [*Increase in detection rate detected. Not true disease increase. Fewer sample tested due to insufficient sample volumes (November) and fewer samples 
collected due to festive season (December)].
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4.3.5. Co-infections 
B. pertussis was detected in 42.5% (34/80) of SRI cases as a single pathogen. For the 
remainder of B. pertussis positive cases (46/80, 57.5%), patients were co-infected with 
respiratory bacteria or viruses. Co-infections with respiratory bacteria included 
S. pneumoniae, H. influenzae, Legionella spp. and M. pneumoniae. Co-infections with 
respiratory viruses included influenza, RSV, human metapneumovirus and other viruses 
(adenovirus, enterovirus, parainfluenza, or rhinovirus). 
  
Page 57 of 104 
 
4.4. B. parapertussis 
4.4.1. Comparison of specimen types for the detection of B. parapertussis 
When comparing sputa that were PCR-positive for B. parapertussis it was observed that 39% 
(7/18) of the B. parapertussis positive cases were mucoid and 50% (6/12) of the cases had a 
positive Bartlett’s score (Table 8). A similar trend was observed for sputa that was PCR-
negative B. parapertussis. 
 
Table 8: Macroscopic (N=1615) and Bartlett’s score (N=1088) evaluation of induced sputum 
collected from SRI cases, by B. parapertussis PCR result, South Africa, June 2012 – October 
2014 (N=2703). 
Characteristic 
B. parapertussis 
positive 
B. parapertussis 
negative Total  
n/N (%)  n/N (%) 
Macroscopic 
evaluation 
      Saliva 5/18 (28) 457/1597 (29) 
 
   Mucoid 7/18 (39) 626/1597 (39) 
 
   Purulent 5/18 (28) 350/1597 (22) 
 
   Blood stained 1/18 (6) 164/1597 (10) 
 
Total 18 1597 1615 
Bartlett’s score 
  
 
   Negative 1/12 (8) 344/1076 (32) 
 
   0 5/12 (42) 285/1076 (26) 
 
   Positive 6/12 (50) 447/1076 (42) 
 
 Total  12  1076  1088 
Negative (combined -1 and -2 score) = presence of between 10 – 25 (-1) and >25 (-2) epithelial cells.  
0= presence of <10 neutrophils. 
Positive= (combined +1 and +2 score) = presence of between 10 – 25 (+1) and >25 (+2) neutrophils. 
Good quality sputum should have a positive Bartlett’s score and should not be saliva. 
All percentages rounded off. 
 
There was 1 case that tested positive for B. parapertussis on NP alone and 12 cases that 
tested positive on IS alone. No statistical analysis was performed to compare specimen types 
for the detection of B. parapertussis as numbers were too small.   
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4.4.2. Comparison of B. parapertussis positive and negative cases by surveillance 
group 
Table 9: Comparison of B. parapertussis positive cases and B. parapertussis negative cases 
in patients presenting with severe respiratory illness, South Africa, June 2012 – October 2014 
(N=3982). 
Characteristic 
B. parapertussis PCR result – SRI cases 
OR  
(95% CI)
2
 
B. parapertussis positive 
n/N (%) 
B. parapertussis negative 
n/N (%)  
Year 
  
 
   2012 15/1170 (1) 1155/1170 (99) reference 
   2013 21/1649 (1) 1628/1649 (99) 1 (0.5 – 2) 
   2014 4/1163 (0.3) 1159/1163 (100) 0.3 (0.09 – 0.8) 
Gender 
  
 
   Female 17/1962 (0.9) 1945/1962 (99) reference 
   Male  23/2013 (1) 1990/2013 (99) 1 (0.7 – 2) 
Age group 
  
 
   <1 13/880 (1) 867/880 (99) reference 
   1-4 8/497 (2) 489/497 (98) 1 (0.4 – 3) 
   5-14 1/116 (0.9) 115/116 (99) 0.6 (0.08 – 4) 
   15-24 3/208 (1) 205/208 (99) 1 (0.3 – 3) 
   25-44 11/1301 (0.9) 1290/1301 (99) 0.6 (0.3 – 1) 
   45-64 3/761 (0.4) 758/761 (99) 0.3 (0.07 – 0.9) 
   ≥65 1/210 (0.5) 209/210 (100) 0.3 (0.04 – 2) 
Fever history 
  
 
   No 29/2338 (1) 2309/2338 (99) reference 
   Yes 10/1606 (0.6) 1596/1606 (99) 0.5 (0.2 – 1) 
HIV status 
  
 
   Uninfected 17/1556 (1) 1539/1556 (99) reference 
   Infected 17/1896 (0.9) 1879/1896 (99) 0.8 (0.4 – 2) 
HIV treatment 
  
 
   No 6/718 (0.8) 712/718 (99) reference 
   Yes 4/905 (0.4) 901/905 (100) 0.5 (0.1 – 2) 
Symptom duration 
  
 
   <7 days 26/2131 (1) 2105/2131 (99) reference 
   7-20 days 4/831 (0.5) 827/831 (100) 0.4 (0.1 – 1) 
   ≥21 days 10/939 (1) 929/939 (99) 0.9 (0.4 – 2) 
Underlying illness
1
 
  
 
   No 39/3536 (1) 3497/3536 (99) reference 
   Yes 1/437 (0.2) 436/437 (100) 0.2 (0.03 – 2) 
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ICU 
  
 
   No 38/3832 (1) 3794/3832 (99) reference 
   Yes 2/58 (3) 56/58 (97) 4 (0.8 – 15) 
Antibiotic treatment 
(24 hours)  
  
 
   No 38/3771 (1) 3733/3771 (99) reference 
   Yes 2/187 (1) 185/187 (99) 1 (0.3 – 4) 
Hospital duration 
  
 
   <2 days 7/396 (2) 389/396 (98) reference 
   2-4 days 14/1101 (1) 1087/1101 (99) 0.7 (0.2 – 1.7) 
   5-7 days 10/965 (1) 955/965 (99) 0.5 (0.2 – 1.5) 
   ≥8 days 9/1261 (0.7) 1252/1261 (99) 0.3 (0.1 – 1.0) 
Viral co-infection 
  
 
   No 18/2166 (0.8) 2148/2166 (99) reference 
   Yes 21/1786 (1) 1765/1786 (98) 1 (0.8 – 3) 
Outcome 
  
 
   Survived 39/3516 (1) 3477/3516 (99) reference 
   Died 1/338 (0.3) 337/338 (100) 0.3 (0.04 – 2) 
Facility 
  
 
   Edendale 18/1770 (1) 1752/1770 (99) reference 
   KTHC 22/2212 (1) 2190/2212 (99) 1 (0.5 – 1.8) 
Abbreviations: SRI=Severe respiratory illness; KTHC=Klerksdorp-Tshepong hospital complex; N/A=Not 
applicable; OR=Odds ratio; CI=confidence interval. 
1
Patients with previously diagnosed chronic conditions including asthma, chronic lung diseases, cirrhosis/liver 
failure, chronic renal failure, heart failure, valvular heart disease, coronary heart disease, immunosuppressive 
therapy, splenectomy, diabetes, burns, kwashiorkor/marasmus, nephrotic syndrome, spinal cord injury, seizure 
disorder, emphysema, or cancer. 
All percentages rounded off. 
2
Bold font indicates statistical significance. 
 
When comparing B. parapertussis positive cases to negative cases, differences were observed 
by year of study and age group (Table 9). In 2014, the detection rate of B. parapertussis was 
significantly lower when compared to 2012 [OR=0.3 (95% CI 0.09 – 0.8)]. In addition, 
positive cases were less likely to be detected in the 45-64 year age group when compared to 
the <1 year age group [OR=0.3, 95% CI 0.07 – 0.9)]. 
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Table 10: Comparison of B. parapertussis positive cases and B. parapertussis negative cases 
in patients presenting with influenza-like illness, South Africa, June 2012 – October 2014 
(N=3243). 
Characteristic 
B. parapertussis PCR result – ILI cases 
OR  
(95% CI)
2
 
B. parapertussis positive 
n/N (%) 
B. parapertussis 
negative n/N (%)  
Year 
  
 
   2012 3/970 (0.3) 967/970 (100) reference 
   2013 10/856 (1) 846/856 (99) 4 (1.04 – 14) 
   2014 5/1417 (0.4) 1412/1417 (100) 1.1 (0.2 – 4.7) 
Gender 
  
 
   Female 12/2031 (0.6) 2019/2031 (99) reference 
   Male  6/1164 (0.5) 1158/1164 (99) 0.8 (0.3 – 2.3) 
Age group 
  
 
   <1 1/303 (0.3) 302/303 (100) reference 
   1-4 9/614 (1) 605/614 (99) 4 (0.6 – 36) 
   5-14 2/514 (0.4) 512/514 (100) 1 (0.1 – 13) 
   15-24 1/453 (0.2) 452/453 (100) 0.7 (0.04 – 11) 
   25-44 3/971 (0.3) 968/971 (100) 0.9 (0.1 – 9) 
   45-64 2/333 (0.6) 331/333 (99) 2 (0.2 – 20) 
   ≥65 0 54/54 (100) N/A 
Fever history 
  
 
   No 3/316 (1) 313/3166 (99) reference 
   Yes 15/2868 (0.5) 2853/2868 (99) 0.2 (0.1 – 2) 
HIV status 
  
 
   Uninfected 11/1954 (0.6) 1943/1954 (99) reference 
   Infected 4/855 (0.5) 851/855 (100) 0.8 (0.3 – 3) 
HIV treatment 
  
 
   No 2/293 (0.7) 291/293 (99) reference 
   Yes 2/461 (0.4) 459/461 (100) 0.6 (0.1 – 5) 
Symptom duration 
  
 
   <7 days 14/2862 (0.5) 2848/2862 (100) reference 
   7-20 days 1/180 (0.6) 179/180 (99) 1 (0.1 – 9) 
   ≥21 days 2/67 (3) 65/67 (97) 6 (1.4 – 28) 
Underlying illness
1
 
  
 
   No 17/3021 (0.6) 3004/3021 (99) reference 
   Yes 1/164 (0.6) 163/164 (99) 1 (0.1 – 8) 
Viral co-infection 
  
 
   No 13/1712 (0.8) 1699/1712 (99) reference 
   Yes 5/1512 (0.3) 1507/1512 (100) 0.4 (0.2 – 1) 
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Facility 
  
 
   Edendale gateway 15/2385 (0.6) 2370/2385 (99) reference 
   Jouberton 3/858 (0.4) 855/858 (100) 2 (0.5 – 6) 
Abbreviations: ILI=Influenza-like illness; N/A=Not applicable; OR=Odds ratio; CI=Confidence interval. 
1
Patients with previously diagnosed chronic conditions including asthma, chronic lung diseases, cirrhosis/liver 
failure, chronic renal failure, heart failure, valvular heart disease, coronary heart disease, immunosuppressive 
therapy, splenectomy, diabetes, burns, kwashiorkor/marasmus, nephrotic syndrome, spinal cord injury, seizure 
disorder, emphysema, or cancer. 
2
Bold font signifies statistical significance. 
All percentages rounded off. 
 
Positive and negative B. parapertussis cases with ILI differed by year of study and symptom 
duration (Table 10). In 2013 the detection rate of B. parapertussis was significantly higher 
when compared to 2012 [OR=4 (95% CI 1.04 – 14)]. In addition there was a 6-fold increased 
risk for testing positive for B. parapertussis if patients presented with ≥21 days symptom 
duration when compared to patients presenting with <7 days symptom duration [OR=6 (95% 
CI 1.4 – 28)].  
 
Two control individuals were PCR-positive for B. parapertussis. Both were female and 
presented at the Edendale Gateway clinic. Individual 1 was a 1 year old and HIV infected 
whilst individual 2 was 2 years of age and HIV uninfected. 
 
B. parapertussis disease was observed in all age groups for SRI cases (Figure 8). The highest 
prevalence was observed in the 1-4 year age group (1.6%, 8/497). For ILI cases, the highest 
prevalence was also observed in the 1-4 year age group (1.5%, 9/614) (Figure 9). No cases 
were detected in the ≥65 year age group. 
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Figure 8: Detection rate of B. parapertussis in cases presenting with severe respiratory illness by age group, South Africa, June 2012 – October 
2014 (N=3973). 
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Figure 9: Detection rate of B. parapertussis in cases presenting with influenza-like illness by age group, South Africa, June 2012 – October 2014 
(N=3242).
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Table 11: Attributable fraction of B. parapertussis diseases in patients with severe respiratory illness and influenza-like illness, South Africa, 
June 2012 – October 2014 (N=8569). 
Surveillance group 
Cases 
tested 
Cases 
positive 
Detection rate 
(%) 
Odds ratio (95% CI) Attributable fraction (95% CI) 
SRI  3982 40 1% 4.97 (1.14 – 21.63) 79.89 (12.52 – 95.38) 
ILI  3243 11 0.3% 4.82 (0.97 – 24.03) 79.25 (-3.47 – 95.84) 
Controls 1344 2 0.1% reference reference 
Abbreviations: SRI=Severe respiratory illness; ILI=Influenza-like illness; CI=Confidence interval. 
Attributable fraction calculated for SRI cases using positive nasopharyngeal and induced sputum positive specimens. 
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4.4.3. Attributable fraction of B. parapertussis disease  
For cases presenting with SRI, the B. parapertussis attributable fraction was 80% (95% CI 
12.52 – 95.38) after adjusting for HIV status and age group (Table 11). This result indicates 
that 80% of B. parapertussis SRI cases could be attributed to B. parapertussis infection. 
Within the ILI surveillance population there was no attributable fraction of disease. 
 
4.4.4. Seasonality of B. parapertussis disease 
B. parapertussis disease showed no distinct seasonality (Figure 10). The highest detection 
rate was observed in August of 2012 (3.8%, 8/212). Only 4 cases positive for 
B. parapertussis were detected in 2014. 
 
4.4.5. Co-infections 
B. parapertussis was detected in 35% (14/40) of SRI cases with no other respiratory bacterial 
or viral pathogen. The other 65% (26/40) of B. parapertussis positive cases were co-infected 
with respiratory bacteria or viruses, S. pneumoniae and M. pneumoniae, influenza, RSV, 
human metapneumovirus and other viruses (adenovirus, enterovirus, parainfluenza, and 
rhinovirus). 
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Figure 10: Seasonality of B. parapertussis by month and year, South Africa, June 2012 – October 2014 (N=3982). 
[*Increase in detection rate detected. Not true disease increase. Fewer samples collected due to festive season (December)]. 
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4.5. B. bronchiseptica 
During the surveillance period B. bronchiseptica was detected in 4 cases only (Table 12). 
One case tested positive on both specimen types whilst 3 cases tested positive on an NP 
specimen only. Three cases were co-infected with rhinovirus and 1 case (with no co-
infection) was HIV positive.  
 
Table 12: Summary of cases PCR positive for B. bronchiseptica, South Africa, June 2012 – 
October 2014 (N=8569). 
Characteristic Case 1 Case 2 Case 3 Case 4 
   Gender Male Male Male Female 
   Race Black Black Black Black 
   Age (years) 63 1 1 45 
   HIV status Uninfected Uninfected Uninfected Infected 
   Underlying illness Yes Yes No No 
   Surveillance group SRI SARI ILI SRI 
Abbreviations SRI=Severe respiratory illness; SARI=Severe acute respiratory illness; ILI=Influenza-like illness. 
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5. Discussion 
Following the implementation of the pertussis whole-cell vaccine in South Africa in 1950, 
there are limited data describing pertussis in South Africa, as well as a lack of standardised 
molecular methods for pertussis identification. Our study utilised 2 pneumonia surveillance 
platforms (SRI and ILI) to determine the prevalence of B. pertussis at selected sites in South 
Africa. Real-time multiplex and singleplex PCR assays were validated and implemented to 
detect B. pertussis, B. parapertussis, B. holmesii and B. bronchiseptica. In addition, different 
specimen types were evaluated for the detection of these Bordetella species. Of the 8569 
cases enrolled that had specimens taken for testing, 118 [1.4%, 118/8569 (95% CI 1.1 – 1.6)] 
were positive for B. pertussis of which 2% [80/3982 (95% CI 1.6 – 2.5)] were hospitalised, 
1% [32/3243 (95% CI 0.7 – 1.4)] were out-patients and 0.4% [6/1344 (95% CI 0.2 – 1.0)] 
were asymptomatic controls.  
 
Real-time PCR validation 
After reviewing the literature two assays were implemented: the first assay is a three-plex 
which detects the insertion sequences IS481, pIS1001 and hIS1001 and the second assay is a 
singleplex which detects the pertussis toxin ptxS1 (26;27). The multiplex assay detects IS481 
to detect Bordetella spp. (B. pertussis (50-238 copies per genome), B. bronchiseptica (rarely 
detected in humans) and B. holmesii (8-10 copies per genome), pIS1001 for B. parapertussis 
(20-23 copies per genome), and hIS1001 for B. holmesii (3-5 copies per genome). The second 
assay is a singleplex that detects ptxS1 which is a confirmatory target for B. pertussis, 
B. bronchiseptica and B. parapertussis. An internal validation was performed for these assays 
and 100% sensitivity and specificity was obtained for the detection of B. parapertussis, 
B. bronchiseptica and B. holmesii. 95% sensitivity and 100% specificity was obtained for the 
detection of B. pertussis. In addition, all QCMD panels received for 2011, 2013 and 2014 
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were correct. However for the 2012 panel, one DNA extract was reported as a negative. This 
may have been due to the DNA yield in the specimen being too low for the real-time PCR 
assays to detect or due to DNA degradation as the extracts from this panel were stored for 
over a year before it was given to our laboratory by a second laboratory. In addition, no 
expected Ct-values were available for any of the QCMD samples so Ct-values could not be 
compared. With regard to the Ct-values generated for IS481, pIS1001 and ptxS1, it was 
observed that Ct-values generated for IS481 and pIS1001 were 5-10 Cts lower than Cts 
obtained for ptxS1. The lower Ct-values is probably due to the fact that there are multiple 
copies of the insertion sequences (IS481 and pIS1001) in B. pertussis and B. parapertussis, 
compared to the single copy ptxS1gene (28). 
 
One aspect of PCR robustness was demonstrated by the fact that no differences in Ct-values 
were detected when using two different master mixes, namely, TaqMan Gene Expression 
master mix (Applied Biosystems) and the Quanta super mix (Quanta Biosciences). Therefore 
Taqman gene expression master mix was used as it is cheaper and easier to purchase and was 
consistent to the published methodology.  
 
B. pertussis 
IS481 is a multicopy target (50-238 copies per genome), therefore increasing the risk of 
laboratory and PCR contamination (31-33). It is advisable to determine reasonable and 
accurate Ct-value cut-offs when analysing and interpreting PCR data. Many studies published 
thus far have incorporated Ct-value cut-offs similar to our study when using IS481 for the 
detection of B. pertussis. In a Tunisian study from 2007 to 2011, B. pertussis cases were 
defined as PCR positive for IS481 and ptxS1 with a Ct <45, or as Bordetella spp. if they were 
positive for IS481 only with a Ct <45 (28). Of the clinically-confirmed B. pertussis cases, 
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82% tested positive for B. pertussis and 5% tested positive for Bordetella spp by real-time 
PCR. Another study in Norway from 2011 and 2012, enrolling patients of all ages with 
respiratory tract infection, used a Ct cut-off <36 and 36-40 for IS481 (57). Cases positive for 
IS481 with Ct <36 were defined as B. pertussis positive and cases positive with Ct-values of 
36-40 were repeated to confirm results. A study in the United States from 2008 to 2010 
utilised two different Ct cut-off algorithms (58). Prior to 2010, specimens were defined as 
positive for pertussis/parapertussis if they tested positive for IS481 or IS1001 with Ct <38 and 
all specimens with Ct-values of 35-50 were repeated to confirm results. After 2010, 
interpretation was changed to define positivity as Ct-values <35 for IS481 or IS1001. 
Samples with Ct-values of 35-40 were repeated to confirm results. This change in 
interpretation was done to determine if overall positivity would be affected by further Ct cut-
offs, however using both interpretation methods the results remained the same. The CDC 
uses a Ct-value cut-off of 34 for IS481 and/or a Ct-value cut-off of 39 for ptxS1 for 
B. pertussis positivity (26;27). A Ct-value of 35-40 for IS481 and/or a Ct <40 for ptxS1 are 
interpreted as indeterminate for B. pertussis. Any sample with a Ct ≥40 is interpreted as 
negative. In trying to determine appropriate Ct-value cut-offs for our study it was observed 
that many cases that tested positive for IS481 had Ct-values ranging from 35 to 45. These 
results would be defined as indeterminate/negative using the CDC published algorithm. The 
algorithm was therefore modified to interpret all samples with Ct-values <45 as positive and 
to further define as confirmed pertussis (Ct-values <35) or probable pertussis (Ct-values 35-
45) so as not to exclude any cases at this stage (Appendix 5). 
 
In our study, 118 B. pertussis cases were detected, 40% were defined as confirmed pertussis 
and the remaining 60% as probable pertussis. Ideally, in this situation clinical data should be 
used in conjunction with laboratory results to make a definitive diagnosis, however because 
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the case definition for enrollment was based on pneumonia symptoms, no clinical data 
specific for pertussis symptoms were available for any of the positive cases, so this could not 
aid in diagnosis. Therefore, results were stratified by surveillance group and clinical 
characteristics to determine if there were any differences between the confirmed and probable 
pertussis cases. Using univariate analysis, minimal differences were found between 
confirmed and probable pertussis cases. Amongst the hospitalised pertussis cases, more 
probable cases were 45-64 year age group (lower bacterial loads) when compared to the <1 
year age group. This correlates with a study in Japan from 2007 to 2009 which showed that 
adults have a significantly lower bacterial load in both early and late stages of disease 
compared to infants and children (59). For the pertussis cases at the out-patient clinics, more 
probable pertussis cases were detected at the Jouberton facility compared to the Edendale 
Gateway facility. Analysis of characteristics of patients presenting at these facilities did not 
differ and a reason for this could not be determined. 
 
Although there was no clear differentiation between confirmed and probable cases, there 
were three factors that support the fact that the probable cases were true cases. Firstly, from 
the 2013 and 2014 QCMD panels, all B. pertussis samples were correctly identified as 
positive using real-time PCR with Ct-values ranging from 34 to 42. In addition, a subset of 
positive B. pertussis patients (probable and confirmed cases) from 2014 was retrospectively 
interviewed and the majority of these patients reported clinical symptoms consistent with 
pertussis. Furthermore, because surveillance was not specific for pertussis, some of the cases 
may have presented late in pertussis infection where bacterial loads are low, resulting in 
higher PCR Ct-values.  
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In our study the detection rate of B. pertussis in hospitalised and out-patient populations was 
2% and 1%, respectively, which is low compared to detection rates observed in other 
countries. The detection rate observed in our study population could be attributed to the 
surveillance case definition that is not specific for pertussis. All enrolled cases presented with 
possible clinical pneumonia and enrollment criteria were based on pneumonia-related clinical 
symptoms. Studies have shown that pertussis prevalence varies by country; as sample 
populations, diagnostic tests employed, sample types and vaccination type/status varies 
between countries and studies (60-62). A population-based study in Toronto from 1993 to 
2007 found a 9.4% pertussis detection rate amongst patients of all ages. All patients had 
clinical symptoms of pertussis and presented to different public health units in the Greater 
Toronto area (38). Another study conducted in Finland from 1994 to 1997 enrolling out-
patients of all ages with paroxysmal coughing found a B. pertussis prevalence of 16.3% (63). 
A serological study, measuring anti-PT IgG levels, was conducted in Denmark from 2006 to 
2008 to determine the causative agent in patients with cough of unknown aetiology in all 
patients aged 8 years and older (37). Three to 11% (depending on the serological cut-off 
values used) of the population tested positive for B. pertussis. A study conducted in Ohio 
from 2010 and 2011 enrolling patients of all ages, to determine the epidemiological and 
laboratory features of an outbreak of pertussis-like illness found 29% of the population to be 
positive for B. pertussis (64). 
 
B. pertussis is known to cause severe disease in infants, milder disease in children and 
asymptomatic infection in adolescents and adults, who are the source of infection for younger 
children (65). In our study, pertussis was detected in all age groups. Amongst hospitalised 
patients, the highest detection rate was in the older age groups whereas the detection rate in 
less severe patients was highest in children <5 years. Other studies have shown a higher 
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prevalence in children which is contradictory to our study. From 2008 to 2011, approximately 
311 laboratory-confirmed B. pertussis cases were reported to the South African Department 
of Health (66). Sixty-seven percent were infants <3 months old and 22% were infants <6 
weeks old. A Cape Town study enrolling children ≤7 years of age, from June 1988 to April 
1989, using serology, found that 50% of the positive cases were infants <6 months, 22% were 
in the 6-11 month age group, 24% were in the 12-59 months age group and 3% in the 60 
months and older age group (41;50). A serological study in Denmark from 2006 to 2008 to 
determine the causative agent in patients with cough of unknown aetiology in all patients 
aged 8 years and older found children between the ages of 8 to 14 years with the highest 
seroprevalence of pertussis (37). A study conducted in Norway from 2011 and 2012 enrolling 
patients of all ages with respiratory tract infection, found the highest burden of B. pertussis 
disease in the 13-21 year age group (57). Results from our study highlighted the increased 
burden of asymptomatic pertussis in the older age groups. The WHO has reported this age 
group as an important source of transmission of B. pertussis to infants too young to be fully 
vaccinated and due to waning vaccine immunity in the older age groups (16). Another study 
in Finland, from 1993 to 1994 in patients of all ages, found a large proportion of pertussis 
cases in the adult age groups, presumably due to decreased protection from B. pertussis 
vaccination with time (63).  
 
Pertussis disease is cyclical with disease peaks observed every two to five years (17;23) and 
disease has been shown to peak in the summer and autumn months (65). Studies have shown 
differing pertussis seasonality and it has been stated that pertussis disease is not consistent by 
place or time (18). In Canada, from 1993 through 2007, pertussis infection peaked in the 
autumn and winter months (38). In a South African study, from 2008 and 2009, an increase in 
pertussis disease was detected in the autumn and winter months (51). During the 2010 
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California epidemic, pertussis disease peaked in summer and autumn (67). In our study 
B. pertussis disease did not follow an obvious seasonal pattern, however disease peaks were 
observed in the late winter and early spring months (July – September). The highest detection 
rate was observed in August 2014 (15%). As the increase was only observed at the Jouberton 
clinic and the Tshepong hospital in the North West province, it was investigated to determine 
if it was due to IS481 PCR contamination or a true reflection of disease and possibly an 
outbreak. Various environmental swabs were collected from the two facilities and a subset of 
the positive B. pertussis patients were interviewed to determine if there was an 
epidemiological link between the cases. All environmental swabs were PCR negative and an 
audit of all laboratory processes and testing ruled out contamination. It was thus concluded 
that the 15% increase was a true reflection of disease; however it was not an outbreak as no 
epidemiological link could be found between the cases.  
 
B. pertussis was detected in both NP and IS specimens. A lower detection rate (0.5%) was 
observed in NP specimens compared to the detection rate (1.8%) in IS specimens. This 
implies that IS may be a better specimen type for the detection of B. pertussis. This result 
contrasts with the recommendation that NP specimens are the preferred specimen type for 
pertussis diagnostics (17;18;23;52). It has been shown that there is specific binding of 
B. pertussis to the ciliated epithelial cells of the nasopharyx upon attachment to host cells 
during disease manifestation (68). Only in the absence of an immune response does the 
bacterium move to the ciliated epithelial cells of the trachea and bronchi (16;17;19). The use 
of IS for pertussis diagnosis has been suggested by WHO but data supporting this specimen 
type for diagnostics are lacking (52). In the laboratory, sputum is graded microscopically 
using the Bartlett’s score and macroscopically to determine specimen quality, and specimens 
that are graded negatively may be rejected for use in diagnostics (69). When comparing the 
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quality of IS received in our study for testing to the PCR results obtained for these specimens, 
it was found that the macroscopic and Bartlett’s score evaluation did not influence PCR 
results for the detection of B. pertussis and B. parapertussis. In the clinical environment IS is 
difficult to obtain from patients, in particular children. Patients are sometimes too sick to 
cough up sputum and only patients that have a severe respiratory infection can produce 
sputum. This may challenge the routine collection of IS for pertussis diagnostics. 
 
In our study, cases positive for B. pertussis were, in a few instances, also positive for other 
respiratory viruses (influenza, RSV, human metapneumovirus or other viruses) or bacteria 
(S. pneumoniae, H. influenzae, Legionella spp. or M. pneumoniae). In Brazil in 2013, in 
infants with suspected pertussis, approximately 5% of B. pertussis cases were co-infected 
with respiratory viruses (RSV, parainfluenza, adenovirus or influenza) (70). Authors 
concluded that cases that were co-infected had to be further analysed to determine the true 
causative agent of disease, however the majority of cases did have the classical pertussis 
symptoms. Another study in Norway in 2011 showed that a proportion of cases positive for 
B. pertussis were also co-infected with either M. pneumoniae, C. pneumoniae or influenza 
virus (57). No conclusions regarding the causative agents of disease were made in the study. 
When co-infections in patients are detected it is difficult to determine which agent is 
responsible for causing disease. For this reason and also to rule out possible B. pertussis 
carriage, the attributable risk for B. pertussis infection was calculated. Approximately 67% 
(95% CI 18.49 – 86.63) of B. pertussis PCR-positive cases with severe respiratory infection 
could be attributed to B. pertussis infection, whilst for milder cases there was no attributable 
risk of B. pertussis infection. 
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When analysing data from children positive for B. pertussis with an available vaccine status it 
was found that there were more children with lower bacterial loads that were fully vaccinated 
for age compared to children who were not fully vaccinated for age. This correlates with a 
study in Japan that showed that bacterial loads in children vaccinated with four doses of 
pertussis vaccines were lower and they had milder infection than unvaccinated infants (59). 
In Germany from 1993 to 1999, children fully vaccinated with the acellular vaccine had 
milder pertussis symptoms and shorter cough duration compared to unvaccinated children 
(71). In our study, only children <5 years of age had vaccine records available on RTHC but 
not all enrolled children had an available RTHC with vaccine records clearly stated. 
Therefore vaccine status and pertussis disease could not be linked as numbers were too small 
and records were not available.  
 
The attack rate of B. pertussis is higher amongst females than males, however the reason for 
this is unknown (68). In our study there was a higher proportion of females positive for 
B. pertussis, however this was not statistically significant. Other studies in Canada (38) and 
South Africa (41;49) have shown a similar result.  
 
Leukocyte and lymphocyte counts of the patients that tested positive for B. pertussis were not 
available. Studies have shown that patients positive for B. pertussis have increased leukocyte 
and lymphocyte counts. A study in Germany from 1992 to 1993 found that cases infected 
with B. pertussis had a mean leukocyte and lymphocyte count of 12500/mm
3
 and 7600/mm
3
 
respectively (72). These counts were significantly higher than the counts found in 
B. parapertussis positive cases. Amongst the infants that tested positive for B. pertussis in a 
Tunisian study from 2007 to 2011, 38% of cases had leukocytosis and 40% of cases had 
lymphocytosis (28). 
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Sub-Saharan Africa has a high HIV burden and HIV-infected children are more susceptible to 
pneumonia than HIV-uninfected children (73). Studies describing B. pertussis infection 
among HIV-infected individuals are lacking. A study in the Free State from 2008 to 2009 
highlighted that 28% of PCR-positive B. pertussis cases were HIV infected and these patients 
all required hospitalisation. Three were younger than 10 weeks of age and 2 of these infants 
required ICU admission (51). No association between HIV and pertussis could be determined 
in this study as the numbers were too small and not all enrolled cases had an HIV result 
available. 
 
For culture of B. pertussis, NP specimens are recommended and should be taken preferably 
within the first two weeks of cough onset (52). In addition specimens should be taken at the 
patient bedside, inoculated into transport medium for pertussis and transported directly to the 
laboratory within 48 hours at room temperature (52). Due to the fastidious nature of 
B. pertussis, culture is difficult (17). In our study NP specimens were not used for culture as 
specimens were transported in UTM which is not ideal as it contains antibiotics which 
impedes culture. Therefore, IS specimens were used; however no positive B. pertussis 
cultures were obtained. This could be due to specimens being stored incorrectly during 
transportation, delay in specimen transportation to the laboratory, bacterial or fungal 
contamination of culture plates following incubation at the laboratory (28). In addition, from 
2014 all PCR-positive B. pertussis patients were retrospectively interviewed and additional 
NP specimens (transported in the recommended Regan-Lowe transport medium) (Media 
Mage, Rooderport, Johannesburg) were taken for culture; however this was not ideal as many 
cases had been treated with antibiotics and some had recovered from infection. Studies using 
culture and real-time PCR have shown that real-time PCR has increased sensitivity for the 
detection of B. pertussis when compared to culture (74;75). A study in Tunisia from 2007 to 
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2011, amongst hospitalised infants, also showed the decreased sensitivity of culture (28). 
During the four-year surveillance period in Tunisia only one sample was culture positive 
from a total of 606 samples tested.  
 
B. parapertussis 
B. parapertussis is closely related to B. pertussis, however it causes a milder form of 
pertussis-like disease in humans as it does not produce pertussis toxin (20;29;76). In our 
study population, the detection rate of B. parapertussis was low in hospitalised and out-
patient individuals and this differed to the detection rates showed in other countries. Again, 
this could be attributed to the broad case definition used for pneumonia surveillance. In 
Tunisia, the prevalence of B. parapertussis in all infants hospitalised from 2007 to 2011 was 
7% (28). In Germany, from 1993 to 1999, a high detection rate of 36% of B. parapertussis 
was found in children vaccinated with acellular pertussis vaccine (71).  
 
B. parapertussis was detected in hospitalised patients of all ages; however in the out-patient 
population, B. parapertussis was detected in all age groups except the ≥65 year group. Cases 
positive for B. parapertussis were more likely to present in the younger age groups than the 
older age groups. The highest detection rate of B. parapertussis in the hospitalised and out-
patient individuals was in the 1-4-year-olds. This detection rate in the 1-4 year age group is 
consistent with other studies. Disease caused by B. parapertussis is most common during the 
first five years of life (68). The mean age of children positive for B. pertussis and 
B. parapertussis in a German study from 1993 to 1999 were 4.2 years (range 2.2 – 6.0 years) 
(71). Another study in Germany from 1992 to 1993 found that 86% of B. parapertussis cases 
were younger than 6 years of age (72).  
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In our study B. parapertussis disease showed peaks in August of 2012 and then in May and 
July of 2014. Only 4 cases of B. parapertussis were detected in 2014. No true seasonality 
could be determined as the time frame for this data analysis was only two years and five 
months. In the literature there are limited data regarding the seasonality of B. parapertussis. 
There was no seasonal distribution of B. parapertussis in the Tunisian study from 2007 to 
2011 (28). A clinical trial in Italy between 1992 and 1993 highlighted that B. parapertussis 
and B. pertussis disease have a similar seasonal trend (77). Disease caused by both pathogens 
peaked between spring and summer of the study period. 
 
Studies have shown that the symptom duration in B. parapertussis cases is significantly 
shorter than the symptom duration in B. pertussis cases (63;71;72;78). We did not analyse 
this outcome as one of the criteria for enrollment was symptom duration so this would have 
biased the result. In addition cases did not present based on classic pertussis/parapertussis 
symptoms but had lower respiratory tract infection.  
 
None of the hospitalised and out-patient cases positive for B. parapertussis were co-infected 
with B. pertussis. This differed to what has been published in the literature as B. pertussis and 
B. parapertussis co-infection is common, however, no studies have shown that co-infection 
with B. pertussis and B. parapertussis causes an exacerbation of disease (68). Furthermore, 
infection with one organism does not make the host more susceptible to the second organism. 
From 1994 to 1997 a study in Finland showed that approximately 7.2% of the total 
population studied was co-infected with B. pertussis and B. parapertussis (63). In a Tunisian 
study from 2007 to 2011, 8% of infants tested were positive for B. pertussis and 
B. parapertussis (28).  
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Similar to B. pertussis, the attributable risk for B. parapertussis was calculated as cases that 
were positive for B. parapertussis were co-infected with other respiratory bacteria and/or 
viruses. The attributable risk was 80% (95% CI 12.52 – 95.38) indicating that 80% of cases 
positive for B. parapertussis in the SRI population were sick due to B. parapertussis. The 
remaining 20% of B. parapertussis positive cases may be attributed to the co-infecting 
bacteria or viruses. 
 
B. bronchiseptica 
B. bronchiseptica is a commensal of the respiratory tract and a cause of respiratory disease in 
both wild and domesticated animals (79). This pathogen has been rarely associated with 
disease in humans (68). Transmission usually occurs from animals to children or animal-
caretakers, causing mild respiratory tract infections to pertussis-like symptoms (80).  
 
In our surveillance four cases tested positive for B. bronchiseptica. Three patients were 
hospitalised and 1 presented as an out-patient. No data regarding animal contact were 
available for any of these patients and 2 of the 4 cases had underlying illnesses. In 1981 Byrd 
and coworkers described a chronic renal failure patient on dialysis who developed 
B. bronchiseptica peritonitis (81). The patient was in contact with a domesticated dog 
resulting in contamination of the peritoneal catheter. In 1991 Woolfrey and Moody published 
a summary of 25 cases positive for B. bronchiseptica dating back to 1911 with the majority 
of cases having a respiratory illness (79). Of the 25 cases, two had respiratory tract infections 
and an underlying illness; however none had animal contact prior to B. bronchiseptica 
disease onset. 
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Only one B. bronchiseptica patient was HIV infected with no co-infecting bacterial or viral 
pathogen detected. B. bronchiseptica disease has been associated with HIV. A study by 
Dworkin et al., found nine cases positive for B. bronchiseptica all of whom were HIV 
infected (82). All cases had either mild or severe respiratory tract infections. Three of the 
nine cases had contact with a domestic animal. A case report published in 1994 described an 
HIV-positive patient suffering with pneumonia caused by B. bronchiseptica (83).  
 
Challenges and limitations  
The SRI/ILI study is ongoing; however, only data for 2 years and 5 months are presented in 
this dissertation. The data generated thus far are limited for conclusions to be drawn as the 
number of positive cases was small and limited statistical analyses could be performed. In 
addition patients were enrolled only at 2 sentinel sites in South Africa and the data generated 
is not representative of the entire population. With regard to the interpretation of the PCR 
data, no definitive conclusions regarding the probable pertussis cases could be made. All 
positive cases were analysed irrespective of Ct-values as South Africa has limited pertussis 
data and our study aided in creating baseline data for future studies. In order to make more 
definitive conclusions surveillance needs to continue. B. pertussis could not be cultured 
therefore no molecular characterisation could be carried out to determine if the strains 
circulating in South Africa were also lacking the vaccine antigen pertactin as seen quite 
recently in Europe and the United States following the switch from the whole-cell to the 
acellular pertussis vaccine.  
6. Conclusions and future research 
Our study provides some baseline data for B. pertussis, B. parapertussis and 
B. bronchiseptica in South Africa, even though the case definitions were not ideal for the 
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detection of these pathogens. In addition, real-time PCR assays were validated and 
implemented in our laboratory and are now routinely used for both diagnosis and 
surveillance. No definitive conclusions could be made regarding the probable pertussis cases 
and whether Ct-value cut-offs of 35 should be used to exclude cases, however based on the 
findings discussed above we were confident in reporting these cases as true cases. In addition, 
a subset of positive samples will be sequenced to confirm positive PCR results. Pertussis 
surveillance will continue using the SRI/ILI platforms and will be expanded to other sites in 
the country, namely, Gauteng, Mpumalanga and Western Cape provinces, generating 
additional data more representative of the South African population. More defined case 
definitions for identification of pertussis disease will be incorporated into the case 
investigation forms i.e. upon enrollment patients will be asked if they experienced classical 
pertussis symptoms (whooping cough, posttussive vomiting, and apnoea) prior to enrollment. 
Furthermore, an additional nasopharyngeal specimen will be taken from all cases that have 
suspected pertussis upon enrollment and these specimens will be used predominantly for 
culture. These specimens will inoculated into the transport medium for pertussis and 
transported within 48 hours to the laboratory to possibly increase the chance of obtaining an 
isolate. If B. pertussis cultures are obtained, the isolates will be used to determine the 
molecular epidemiology of the circulating isolates. 
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7. Appendices 
Appendix 1: Case investigation form for the SRI study 
SARI: Severe Acute Respiratory Infection Surveillance in South Africa 
Clinical Case Investigation Form 
National Institute for Communicable Diseases: Epidemiology & Surveillance Unit (ESU) 
TEL: 011 386 6234 OR 011 555 0353          FAX: 011 386 6077 
  
 
SO initials:                             Study number:                                                                               
Date completed: 
 
 
D D M M Y Y Y Y 
 
1.Patient Hospitalised at:    CHBH                    Selby                       Mapulaneng                 Matikwana                           
Edendale 
  
 
2. Age group:                      >2 days< 3months                                   ≥3 months< 5years                      ≥ 5 years 
 
3. Date of birth (DOB):     
D D M  Y Y Y Y 
                                                                              
 
3.1. If DOB unknown, please enter age: years _______ or  months  ______  or days 
_________ 
4. Admission Diagnosis:   Neonatal Sepsis           Bronchiolitis           Bronchopneumonia        Pneumonia           TB 
 
 Lower respiratory Tract Infection                  Bronchitis          Other            
specify:______________________________________ 
5.Date of admission  
D D M M Y Y Y Y 
                                           
 
6. What is the interviewee’s relationship to the participant? Self            Parent/caregiver        Other     ,  
Specify______________ 
 
7. Gender:  Male                Female 
 
 
8.Race:  Asian/Indian                   Black             White                   Coloured   
 
9. What is your house made of?  Bricks            Iron sheeting                   Mud                    Other                 
Specify____________ 
 
 
10. Number of rooms used for sleeping?  
__________________ 
11. Number of people living in house? _______________ 
D D M M Y Y Y Y 
12. Date of onset of symptoms:  
 
Note: to fit the case definition this should be ≤ 7days from the day of admission 
Note: Complete the signs and symptoms at the time of admission, some of the signs or symptoms may have 
resolved by the time you interview the patient. This information should be available in the patient records 
 
13. History of fever?  Yes          No             Unknown     
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14.  Maximum recorded temperature within 24 hours of admission  _____._____ 
o
C (##.#
o
C) Temperature not recorded  
 Note: Record the maximum temperature recorded in the clinical notes or a temperature taken by the 
surveillance oficer within 24 hours of admission if no temperature in the file 
D D M M Y Y Y Y 
14.1 Date temperature recorded?  
 
 
15. Respiratory Rate: ____________ breaths per minute               Not recorded 
Note: Complete the following for children < 5years, skip to Q17 if patient ≥5 years 
 
16.  Were any of the following signs and symptoms present? 
 Cough  Y N 
Difficulty breathing  Y N 
Chest in drawing 
(retraction)  
Y N 
Stridor in a calm 
child  
Y N 
Tachypnoea/respiratory 
distress 
(2mnth- 1 year RR>50, 1-5 
RR>40) 
Y N 
Diarrhoea    
(>3 loose stool per day)  
Y 
 
N 
 
Unable to drink or 
breast feed   
Y N    Vomits everything  Y N Convulsions  Y N 
Lethargy  Y N Unconsciousness  Y N  Any vomiting  Y 
 
N 
 
 
 
In the 7 Days prior to onset of symptoms have you: 
 
17. Had direct contact with dead/dying birds? Y           N 
 
18. Visited a village/area where there have been unusual deaths of poultry or wild birds? Y              N 
  
19. Had close contact with a person who died of an acute respiratory illness? Y         N  
 If no skip to question 20, if yes continue with 19.1 
19.1 When did this 
person die?  
 
D D M M Y Y Y Y 
 
19.2 How long was this person sick for? Days       Weeks          
Months 
 
19.3 Do you know the cause of the illness? Y           
N  
 
19.4 If yes what was the cause? 
__________________________ 
 
20. Do you do any of the following types of work? Veterinarian/animal health worker           Laboratory worker               
Health care worker        
 
 Backyard  chicken keeper                         Farm worker                    Abattoir worker                          None   
 Note: if yes to any of the questions (17-20) notify study doctor who will decide if the patient should be referred 
to the Department of Health for further investigation for suspected Avian influenza. 
Note: Skip to question 23   if child less than 12 years 
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21. Do you drink alcohol? Y          N 
21.1 If yes, how many units per week?________________________ 
 
22. Do you currently smoke? Y          N 
Note: If yes skip to Q 23 
 
 
22.1   If no have you smoked in the past?  Y                
N 
Note: If  no skip to Q 23 
 
22.2 If yes date of stopping? 
D D M M Y Y Y Y  
 
 
23. Do you have any underlying illness or condition at the moment?    Y                  N 
Note: check patient notes for details if necessary. If no skip to Question 24 
 
Asthma                     Y N 
Other chronic lung diseases e.g 
bullous lung disease                       
 
Y 
N CVA/Stroke   Y N 
Cirrhosis/Liver failure Y N Chronic renal failure Y N Heart Failure  Y N 
Valvular heart disease Y N 
Coronary artery disease(except 
H/T) 
Y N Pregnancy Y N 
Organ transplant Y N 
Any immunosuppressive therapy, 
cortisone, chemotherapy, 
radiation therapy 
Y N Sickle cell Y N 
Splenectomy Y N Diabetes Y N Burns Y N 
Immunoglobulin deficiency Y N Autoimmune disease, SLE Y N 
Kwashiokor/marasmu
s 
Y N 
Nephrotic syndrome Y N Spinal cord injury Y N Seizure disorder Y N 
Prematurity Y N Obesity / BMI >=30 Y N COPD/ Emphysema Y N 
Malignancy/cancer Y N If yes specify 
Does the patient live in an 
institution/care facility 
Y N If yes name institution 
 
24. Has the patient been admitted to hospital in the last 12 months? (prior to this admission) Y          N        Unknown 
Note:  If no or unknown skip to Q25 
 
D D M M Y Y Y Y 24.1What was the date that you were discharged from your last hospital admission? 
Note: please fill in 01 for the day if the patient does not know the day(must complete 
month & year) 
 
24.2 Was the patient admitted more than once in the past year? 
Y       N 
Note: If no skip to Q 25 
24.3 If yes how many times? __________ 
Note: if  patient  ≥5 skip to 26 
25. Did the mother have an HIV test during pregnancy? Y          N                 unknown                   
 
Note:  If no/unknown skip to Q26 
25.1 If yes what was the result?      Positive           Negative             Unknown  
Note:  If no/unknown skip to Q26 
 
25.2 What is the source of the results? Verbally from the mother           RTHC              other       
specify___________________________ 
 
26.Has the  patient been  tested for HIV prior to this admission: Yes           No            Unknown  
 
Note: if no/ unknown skip to Q27 
26.1 if yes, what was the result?  Positive            Negative                                   Unknown  
 
Note: if negative/ unknown skip to Q27      
D D M M Y Y Y Y 
26.2 if positive, date of diagnosis? 
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26.3 Currently on ART?  Y             N         Unknown 
26.3.1 If yes date of initiation of 
ART  D D M M Y Y Y Y 
 
 
26.4 Bactrim prophylaxis taken currently? Y                 N                         Unknown  
 
 
26.4.1 If yes, how long have you taken Bactrim?  _______ Years_______ Months_______  Weeks_______ Days 
 
27. TB treatment in the last year? Y                  N 
Note: If no skip to question 28 
 
27.1 if yes date TB treatment 
initiated  
D D M M Y Y Y Y 
 
 
27.2 Are you still taking TB treatment? Y       N         
Unknown 
 
27.3 If no, date TB treatment 
stopped  
D D M M Y Y Y Y 
 
 
 
 
28. Has the patient been prescribed and taken antibiotics in the 24 hours before this admission? Y             N              
Unknown 
Note: If no/unknown skip to Q 29 
28.1 If yes, what is the name of the antibiotic   1. ________________ 2.________________ 3.__________________ 
AMO Amoxicillin, AMP Ampicillin, AUG Augmentin, CEF Cefuroxime, CIP Ciprofloxacin, CLI Clindamycin, CTX 
Ceftriaxone, DOX Doxycycline, ERY Erythromycin, PEN Penicillin, TMX/SMX Cotrimoxazole, VAN vancomycin. If other 
please specify  
 29 Vaccination history,  complete for Children <5 , if aged ≥ 5 years skip to Q 30 
29.1 Was the RTHC seen Yes          No           
 
Note: If no skip to 30 
29.2. If road to health card seen, please complete the details on the following vaccines for all children <5 years old. 
Note: Tick no for vaccines that are not yet due according to the schedule. At 18 months if only the DTP was 
given tick DTP only and N/A for the combined DTP/ HIB , if a combined DTP/ HIB was given tick yes under  
combined and  N/A under DTP only  
Vaccine Dose due Given Date Given 
DTP 
 + 
HIB vaccine 
6 weeks Y N D D M M Y Y Y Y 
 
10 weeks Y N D D M M Y Y Y Y 
 
14 week Y N D D M M Y Y Y Y 
 
18 months Y N 
N/
A 
D D M M Y Y Y Y 
 
DTP 18 Months Y  N 
N/
A 
D D M M Y Y Y Y 
 
S. pneumoniae conjugate 
vaccine(PCV7 /Prevnar)  
6 week Y N D D M M Y Y Y Y 
 
14 weeks Y N D D M M Y Y Y Y 
 
9 months Y N D D M M Y Y Y Y 
 
Measles 
9 months Y N D D M M Y Y Y Y 
 
18 months Y N D D M M Y Y Y Y 
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Rotavirus vaccine 
6 weeks Y N 
 
D D M M Y Y Y Y 
 
14 weeks Y N D D M M Y Y Y Y 
    
30. Children aged five and older and  adults 
Vaccine 
 
 
Dose given 
 
 
 
Date given 
 
 
Date unknown 
 
 
 
Pneumococcal Vaccine ( pneumovax)                                              Y N UNK 
D D M M Y Y Y Y 
 
 
 
 
31.Did the patient receive an influenza vaccine in the past 12 months ? 
Vaccine 
 
 
Dose given 
 
 
 
Date given 
 
 
Date unknown 
 
 
 
Influenza vaccine 
Dose 1 Y N UNK D D M M Y Y Y Y 
 
 
 
Dose 2 Y N UNK D D M M Y Y Y Y 
 
 
32. Antibiotics prescribed during this admission   Y               N           Unknown  
If yes complete the table below, if no End 
 PO IVI IMI 
      Date started 
( enter date 
prescribed) 
 
 PO IVI IMI 
Date started 
 
Amoxicillin    D D M M Y Y Y Y 
 
Ampicillin    D D M M Y Y Y Y 
 
Augmentin    D D M M Y Y Y Y 
 
Cefotaxime    D D M M Y Y Y Y 
 
Ceftriaxone 
(Rocephin) 
   D D M M Y Y Y Y 
 
Cefuroxime 
(Zinnat) 
   D D M M Y Y Y Y 
 
Ciprofloxacin 
(Ciprobay) 
   D D M M Y Y Y Y 
 
Clindamycin    D D M M Y Y Y Y 
 
Cotrimoxazole 
(Bactrim) 
   D D M M Y Y Y Y 
 
Doxycycline    D D M M Y Y Y Y 
 
Erythromycin    D D M M Y Y Y Y 
 
Gentamycin     D D M M Y Y Y Y 
 
Penicillin G    D D M M Y Y Y Y 
 
Vancomycin    D D M M Y Y Y Y 
 
Ampiclox    D D M M Y Y Y Y 
 
Metronidazole    D D M M Y Y Y Y 
 
Other Specify  
 
 
QC Performed 
by 
 
□□□      Date: □□/□□/□□□□           
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Appendix 2: Case investigation form for the ILI study 
 
Influenza-Like Illness (ILI) Surveillance 
Case Investigation Form (CIF) 
Centre for Respiratory Diseases and Meningitis 
(CRDM) 
TEL: 011 386 6410 or 011 386 6434  
FAX: 086 723 3569 
 
SO Initials:   
 
 
    ILI/Controls Study ID: 
 
 
Date completed: / /
             (DD/MM/YYYY) 
 
Patient seen at:  Jouberton Clinic                                              Edendale Gateway Clinic   
Note: surveillance oficer to review criteria for all case definitions before making a decision about the case 
definition met. 
ILI                                        Control  
Enrolled in shedding study               Yes                      No                      
1. Date of birth 
(DOB): 
/ /  If DOB unknown, please enter age: _____Years    Months  
  Days  
2. Gender:  Male                             Female      
3. Race: Asian/Indian                   Black                  Coloured                  White                  Other   
 (Specify) ___________ 
4. What is your house 
made of:  
                      Bricks          Iron sheeting                     Mud                 Other    
(Specify) ___________ 
5. Number of rooms used for sleeping? 
______________ 
5.1 Number of people living in the house? 
___________________________ 
6. What is the interviewee’s relationship to the participant?   Self     Parent/Caregiver      Other     (Specify) 
________________________ 
7. Presenting 
complaint: (Tick 
all that apply) 
Sore throat            Runny nose          Headache            Cough          Fever         
Myalgia           
Other    (Specify) _____________________________ 
8. Date of onset of 
symptoms:  
/ /  
Note: Complete the signs and symptoms at the time of the interview. Some of the signs or symptoms may have 
resolved by the time you interview the patient. 
9. Maximum recorded temperature at time of interview ____.____C° (##.#C°)                                   Temperature not 
recorded                  
10. History of 
fever?  
Yes     No     
Unk   
      If yes, date of fever onset: / /  
11. Respiratory Rate: __________ breaths per minute             Not recorded   
12. Patient length (if not recorded, surveillance oficer to measure): ______.______cm          Percentile (if patient < 5 
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years) ________          Unk   
12.1 Patient weight (if not recorded, surveillance oficer to measure): ______.______kg           Percentile (if patient < 5 
years) ________          Unk   
12.2 Mid upper arm circumference (MUAC) (for patients < 5 years of age only) _____________________ cm  
13. Mental status of the patient (based on AVPU) 
Alert             Disorientated                                         Stuporous                                 Comatose                     
Sedated                      Unknown   
                           (responds to verbal commands)              (responds to painful stimuli) 
14. Were any of the following signs and symptoms present? 
Cough Y N Sore throat Y N Difficulty breathing Y N 
Headache Y N Rhinorrhoea Y N Myalgia Y N 
Diarrhoea (>3 loose 
stool per day) 
Y N 
Symptoms presents for 
≤3 days 
Y N 
Symptoms present for 4-7 
days 
Y N 
Note: Complete the following questions for patients ≥ 18 years, if patient < 18 years skip to Q 18. 
15. Do you drink alcohol?                                  Yes          
No   
If yes, how many units per week? _______________ 
16. Do you currently smoke?                            Yes          
No   
If yes, how many cigarettes do you smoke per day? 
______________ 
16.1   If no, have you smoked in the past?       Yes          
No   
If yes, date stopped smoking: / /  
17. Do you currently or have you ever worked in a mine before?  Yes        No        Unk   
Note: If no or unknown, skip to Q18 
17.1   If yes, date started working in the mine: / /                Date unknown   
17.2   If working in a mine or worked in a mine before, when did you stop working in the mine?   / /                 
Ongoing    
                                                                                                                                                                              Date 
Unknown   
17.3   If currently or worked in mine before, what type of mine/s? (tick all that apply) 
Gold            Coal            Platinum            Asbestos            Other     (Specify) 
__________________________________ 
18. Do you have any underlying illness or condition at the moment?     Yes             No   
Note: If no skip to Q 19 
Asthma  Y N Other chronic lung disease Y N CVA/Stroke Y N 
Cirrhosis/Liver failure Y N Chronic renal failure Y N Heart failure Y N 
Valvular heart disease Y N 
Coronary artery disease (except 
H/T) 
Y N Pregnancy  Y N 
Organ transplant Y N 
Any immunosuppressive therapy, 
cortisone, chemotherapy, 
radiation therapy 
Y N Sickle cell Y N 
Splenectomy  Y N Diabetes  Y N Burns  Y N 
Immunoglobulin 
deficiency 
Y N Autoimmune disease, SLE Y N 
Kwashiorkor/ 
Marasmus 
Y N 
Nephrotic syndrome Y N Spinal cord injury  Y N 
Seizure 
disorder 
Y N 
Prematurity  Y N Obesity / BMI >=30 Y N COPD/Emphys Y N 
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ema 
Malignancy/Cancer Y N If yes, specify:  
Other  Y N If yes, specify:  
Does the patient live in 
an institution/care 
facility 
Y N If yes, name of institution:  
Note: Complete for patients < 5 years, if patient ≥ 5 years skip to Q 20. 
19. HIV result during pregnancy (mother of patient):     Yes       No       Unk   
Note: If no or unknown skip to Q 20 
19.1 If yes, what was the result?     Positive       Negative        
19.2 What was the source of the results?  RTHC        Laboratory report         Medical records        Verbal        
Other    Specify _________ 
20. Has the patient been tested for HIV prior to this consultation?      Yes       No       Unk   
Note: If no or unknown skip to Q 21 
20.1   If yes, what was the result?  Positive       Negative       Unk              Date of test / /     
date Unk  
Note: If result unknown skip to Q 21 
20.2  What was the source of the results?  RTHC        Laboratory report         Medical records       Verbal       
Other   Specify _________  
Note: If negative skip to Q 21 
20.3   Currently on ART?  Yes       No       
Unknown   
If yes, date of initiation of ART:   / /  
20.4   Bactrim (contrimoxazole/trimethoprim) prophylaxis taken currently?    Yes       No       Unk   
Note: If no or unknown skip to Q 21 
20.5   If yes, how long have you taken Bactrim? _____Years _____Months _____Weeks _____Days 
21. Has the patient been tested for HIV during this consultation?      Yes       No   
Note: if no to Q 21 skip to Q 21.5 
NB:ALL PATIENTS WHO DO NOT HAVE A CONFIRMED CURRENT HIV STATUS SHOULD BE OFERED AN HIV 
TEST 
21.1 If yes, who requested the test?                                Surveillance oficer                     Clinic staff    
21.2 Which test was done?                 Rapid Test                                PCR                              Dry Blood Spot 
(DBS)                                ELISA   
 
21.3 What was the test result?                 Positive                          Negative                     Pending                      
Unknown   
 
Note: Complete for patients < 5 years, if patient ≥ 5 years skip to Q 21.5.  
21.4 If rapid test was done and results are positive, was a DBS collected for testing at NICD?        Yes                                   
No   
Note: if yes, report that DBS was collected also on the laboratory slip. 
21.5 Based on all the information available to you, what is the current HIV status of the patient   Positive               
Negative          Pending                     Unknown   
Note: If current HIV status is positive or pending skip to Q 22 
 
21.6  If current HIV status is negative, what was the source of HIV status? RTHC        Laboratory report         
Medical records       Verbal       Other   Specify ____________________                     
Note: Please ofer  an HIV test to all patients  >5yrs old with a negative  result  reported verbally or taken >6 
weeks before this consultation.  
 
21.7 If current HIV status unknown, why was the patient not tested at this visit? Refused consent                 Other  
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specify_____________________________ 
22. Have you ever taken TB prophylaxis?           Yes     No  
   Unk   
If yes, date TB prophylaxis initiated:  / /
 
Note: If no or unknown skip to Q 23 
22.1   Are you still taking TB prophylaxis?           Yes       No  
   Unk   
If no, date TB prophylaxis stopped:   / /
 
Note: If yes skip to Q 23 
23.   TB treatment in the last 12 months?         Yes       No  
   Unk   
If yes, date TB treatment initiated:    / /
 
Note: If no or unknown skip to Q 24 
23.1   Are you still taking TB treatment?              Yes       No  
   Unk   
If no, date TB treatment stopped:      / /
 
24. Has the patient been prescribed and taken antibiotics in the 24 hours before this interview?      Yes       No       
Unk   
Note: If no or unknown skip to Q 25 
24.1   If yes, what is the name of the antibiotic?     1. ____________________ 2. ____________________ 3. 
____________________ 
AMO Amoxicillin; AMP Ampicillin; AUG Augmentin; CEF Cefuroxime, CIP Ciprofloxacin; CLI Clindamycin; CTX 
Ceftriaxone; DOX Doxycycline; ERY Erythromycin, PEN Penicillin, TMX/SMX Contrimoxazole, VAN Vancomycin. If 
other, specify _________________________  
25. Vaccination history. Complete for patients < 5 years, if patient ≥ 5 years skip to Q 26 
25.1   Is the person being interviewed the primary caregiver of the child?          Yes           No        
Note: If no skip to Q 25.3 
25.2   If yes, has the child ever been vaccinated?       Yes       No       Unk   
Note: Excluding the vaccines given at birth 
25.3   Was the Road to Health Card seen?   Yes            
No    
25.4   Was a copy of the Road to Health Card made?  Yes           
No     
Note: If no skip to Q 26 
25.5  If copy was not made, state reason:     Mother refused             Other (specify) 
______________________________________ 
If Road to Health Card seen, please copy the following information from the card: 
25.6   What is patients’ gestational age:     Term           Pre-term            Not recorded on Road to Health Card   
If pre-term, record gestational age: __________weeks 
25.7   If Road to Health Card seen, please complete the details on the following vaccines for all children < 5 years old 
Note: Tick no for vaccines that are not yet due according to the schedule.  At 18 months if only the DTP was 
given tick DTP only and N/A for the combined DTP/HIB, if a combined DTP/HIB was given tick yes under 
combined and N/A under DTP only 
Vaccine Dose due Given Date given 
BCG Birth  Y N / /  
DTP 
+ 
HIB vaccine 
Dose 1 (6 weeks) Y N / /  
Dose 2 (10 weeks) Y N / /  
Dose 3 (14 weeks) Y N / /  
Dose 4 (18 
months) 
Y N N/
A 
/ /  
DTP only (tick N/A if 
DTP+HIB) 
Dose 4 (18 
months) 
Y N N/
A 
/ /  
S.pneumoniae Dose 1 (6 weeks) Y N / /  
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conjugate vaccine 
(PCV7/13/Prevenar) Batch N°_______________     
Unk    
Dose 2 (14 weeks) Y 
Batch N°_______________     
Unk    
N 
/ /  
Dose 3 (9 months) Y 
Batch N°_______________     
Unk    
N 
/ /  
Catch up Y 
Batch N°_______________     
Unk    
N 
/ /  
Measles 
Dose 1 (9 months) Y N / /  
Dose 2 (18 
months) 
Y N / /  
Hepatitis B 
Dose 1 (6 weeks) Y N / /  
Dose 2 (10 weeks) Y N / /  
Dose 3 (14 weeks) Y N / /  
Rotavirus  
Dose 1 (6 weeks) Y N / /  
Dose 2 (14 weeks) Y N / /  
Note: Complete for patients ≥ 5 years, if patient < 5 years skip to Q 27 
26. Did the patient receive pneumococcal polysaccharide vaccine? 
Vaccine Dose given Date given 
Date unknown  
 Pneumococcal Vaccine (Pneumovax) Y N UNK / /  
27. Did the patient receive an influenza vaccine in the past 12 months (For all patients) 
Vaccine Dose given Date given  
Influenza vaccine 
Dose 1 
Y N UNK 
/ /  Date unknown  
 
Dose 2 
Y N UNK 
/ /  Date unknown  
 
Outcome of the clinic visit:            Discharged                         Referred to hospital                             Died                              
Unknown   
QC Performed 
by:  
Initials:   Date:  / /  
Page 93 of 104 
 
Appendix 3: Primers and probes for real-time detection Bordetella species 
Gene target Respiratory pathogen Sequence 5’-3’ 
IS481-F
a 
B. pertussis, B. holmesii, B. 
bronchiseptica 
CAAGGCCGAACGCTTCAT 
IS481-R
a 
 GAGTTCTGGTAGGTGTGAGCGTAA 
IS481-P
a 
 FAM-CAGTCGGCCTTGCGTGAGTGGG-
BHQ1 
   
hIS1001-F
a 
B. holmesii GGCGACAGCGAGACAGAATC 
hIS1001-R
a 
 GCCGCCTTGGCTCACTT 
hIS1001-P
a 
 LC670-
CGTGCAGATAGGCTTTTAGCTTGAGCGC-
BBQ 
   
pIS1001-F
a 
B. parapertussis TCGAACGCGTGGAATGG 
pIS001-R
a 
 GGCCGTTGGCTTCAAATAGA 
pIS1001-P
a 
 HEX-AGACCCAGGGCGCACGCTGTC-BHQ1 
   
ptxS1-F
a 
B. pertussis, B. parapertussis, 
B. bronchiseptica 
CGCCAGCTCGTACTTC 
ptxS1-R
a 
 GATACGGCCGGCATT 
ptxS1-P
a 
 FAM-AATACGTCGACACTTATGGCGA-PH 
 
 
RNase P-F
b 
RNase P-R
b 
RNase P-P
b 
Human gene present in clinical 
specimens (determines 
presence/absence of inhibitors) 
 
AGATTTGGACCTGCGAGCG 
GAGCGGCTGTCTCCACAAGT 
LC610-TTCTGACCTGAAGGCTCTGCGCG-
BHQ2 
a
 References: (26;27;55), 
b
 References: (54;56). 
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Appendix 4: ATCC control strains used for validation of real-time PCR 
Microorganism ATCC number 
Bordetella pertussis 9797D-5 
Bordetella parapertussis BAA-587D-5 
Bordetella bronchiseptica BAA-588D-5 
Bordetella holmesii 51541 
Bordetella avium 35086 
Bordetella hinzii 51783 
Bordetella petrii BAA-461 
 
Appendix 5: Modified algorithm used for the multi-target real-time PCR assay for the 
identification of Bordetella spp. (26;27) 
PCR targets (Ct <45) 
Interpretation 
IS481 pIS1001 hIS1001 ptx S1 
Positive  (Ct <35) Negative Negative Negative/Positive  B. pertussis (confirmed) 
Positive  (Ct≥35) Negative Negative Negative/Positive  B. pertussis (probable) 
Negative/Positive Negative Positive Negative B. holmesii 
Negative Positive Negative Negative/Positive B. parapertussis 
Negative Negative Negative Positive B. bronchiseptica 
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Appendix 6: Composition of 2011, 2012, 2013 and 2014 QCMD panels 
2011 QCMD Panel
1 2012 QCMD Panel2 2013 QCMD Panel3 2014 QCMD Panel3 
BP1101 B. pertussis BP 1201 B. bronchiseptica  BP 1301 B. bronchiseptica  BP 1401 Negative 
BP1102 B. bronchiseptica  BP1202 B. pertussis BP 1302 B. pertussis BP 1402 B. pertussis 
BP1103 Negative BP1203 B. pertussis BP 1303 B. hinzii BP 1403 B. pertussis 
BP1104 B. bronchiseptica  BP1204 B. pertussis BP 1304 B. pertussis BP 1404 B. pertussis 
BP1105 B. pertussis BP1205 B. pertussis BP 1305 H. influenzae BP 1405 B. pertussis 
BP1106 B. holmesii BP1206 B. pertussis BP 1306 B. pertussis BP 1406 B. pertussis 
BP1107 No DNA BP1207 B. pertussis BP 1307 B. pertussis BP 1407 B. pertussis 
BP1108 H. influenzae BP1208 B. holmesii BP 1308 Negative BP 1408 B. parapertussis 
BP1109 No DNA BP1209 B. bronchiseptica  BP 1309 B. bronchiseptica  BP 1409 H. influenzae 
BP1110 B. pertussis BP1210 Negative BP 1310 B. pertussis BP 1410 B. bronchiseptica  
BP1111 B. hinzii BP1211 B. parapertussis BP 1311 B. parapertussis BP 1411 B. holmesii 
BP1112 B. parapertussis BP1212 H. influenzae BP 1312 B. holmesii BP 1412 B. bronchiseptica  
Abbreviations: QCMD=Quality control for molecular diagnostics. 
1, 2: Panel provided by Infection control laboratory. 
3, 4: Panel provided by QCMD.
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